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Cervical cancer is the most common gynecologic malignancy worldwide. 
Like many other cancers, cervical cancer is thought to evolve from normal tissue, 
through a premalignant stage, cervical intraepithelial neoplasia (CIN), to invasive 
cancer, and develop through a multistep process. Although infection of 
epithelial cells with HPV plays a critical role in the carcinogenesis of the uterine 
cervix (zur Hausen el al., 1991b), the fact that only a minority of HPV-infected 
lesion progresses to invasive cancer over a long period of time suggests that 
additional events are necessary for malignant transformation. 
Recent studies indicate that microsatellite instability (MSI) plays a role in 
the pathogenesis of both sporadic and familial colorectal cancer (Aaltonen et al., 
1993; lonov et al., 1993 & Thibodeau et a!., 1993). MSI is thought to represent 
a type of genomic instability due to the defective mismatch repair (MMR) 
function characterized by an increased mutation rate (Parsons et al., 1993a). 
This in turn may lead to alterations in genes which play a direct role in malignant 
cell transformation and associate with a good prognosis (Thibodeau et al., 1993), 
iii 
or a poor prognosis (Paulson et al., 1996) in various cancers. 
In order to understand the role of MSI in the evolution of cervical neoplasms, 
MSI was determined in CIN-L, CIN-H and invasive cervical carcinoma at ten 
loci, i.e. BAT 25, BAT 26, D2S123, D5S346，D17S250, BAT 40, D3S1263, 
D4S402, D5S406 and D11S912, using radioactive labeling in polymerase chain 
reaction (PCR)-based analysis. We also investigated the correlation between 
these findings and clinicopathological parameters or HPV infection, and looked 
for a better panel of MSI microsatellite markers for detecting MSI status in 
cervical neoplasm. 
The results showed that MSI were observed (in at least one locus) in 0 of 24 
(0.0%) case in CIN-L, 1 of 59 (1.7%) case in CIN-H and 27 of 93 (29.0%) cases 
in cervical carcinoma. The more severe the cervical neoplasm developed, the 
higher the MSI incidence was detected statistically significant (p < 0.05), 
suggesting that MSI may be a late event in cervical tumorigenesis. Patients with 
MSI positive invasive cervical carcinomas were correlated with a significantly 
poor prognosis. However, no correlation was found between the status of MSI 
and the HPV infection. Besides, the five microsatellite markers that we chose 
for MSI detection, i.e., BAT 40, D3S1263, D4S402，D5S406 and D11S912, are 
recommended for MSI detection in cervical neoplasm. 
� 
. In conclusion, the role of MSI as a late event in cervical tumorigenesis and 
iv 
the correlation between the presence of MSI and poor prognosis in cervical 
cancer patients bring out the need for further examination of this phenomenon in 
this and other types of human cancers, which may allow more effective therapies 






































ASCIIS Atypical squamous cells of undetermined signficance 
CIN Cervical intraepithelial neoplasia 
CESf-l Grade 1 cervical intraepithelial neoplasia 
CIN-2 Grade 2 cervical intraepithelial neoplasia 
CIN-3 Grade 3 cervical intraepithelial neoplasia 
CIN-H High grade cervical intraepithelial neoplasia 
CIN-L Low grade cervical intraepithelial neoplasia 
CIS Carcinoma in situ 
FIGO International Federation of Gynecology and Obstetrics 
H&E Haemotoxylin and eosin 
HGSIL High grade squamous intraepithelial lesions 
HNPCC Hereditary non polyposis colonic cancer 
HPV Human papilloma virus 
HSV Herps simplex virus 
LGSIL Low grade squamous intraepithelial lesions 
MICA Microinvasive squamous cell carcinoma 
MIS Microsatellite instability 
MMR Mismatch repair 
MSI-H High frequency microsatellite instability 
MSI-L Low frequency microsatellite instability 
MSS Microsatellite stability 
NCI National Cancer Institute 
OCT Optimal condition temperature 
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ORF Open reading frame 
PGR Polymerase chain reaction 
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RFLP Restriction fragment length polymorphism 
RER Replication error 
SGO Society of Gynecological Oncologists 
STD Sexually transmitted disease 
TBS The Bethesda System 
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Chapter I Introduction 
CHAPTER I INTRODUCTION 
1.1 Cervical Intraepithelial Neoplasia and Cervical Cancer 
Cervical Intraepithelial Neoplasia 
Cervical intraepithelial neoplasia (CIN) is defined as “the spectrum of 
intraepithelial changes beginning as with a generally well-differentiated neoplasm, 
traditionally classified as mild dyplasia, and ending with invasive carcinoma 
(Ferenczy and Wright, 1994)." These changes, confined to the squamous 
epithelium above the basement membrane, include nuclear pleomorphism, loss of 
polarity, abnormal mitoses, and loss of differentiation as cells progress from the 
basement membrane to the surface epithelium. 
Richart (Richart, 1964) coined the term cervical intraepithelial neoplasia 
and in the 1960s devised a grading system for CIN in which lesions are classified 
from grades 1 to 3 based on the percentage of cells from the basement membrane 
to the surface that are undifferentiated. When one third or less of the distance 
from the basement membrane to the surface is involved, the lesions are called 
grade 1 (CIN 1); when more than one third but less than or equal to two thirds is 
involved, grade 2 (CIN 2); and when more than two thirds is involved, grade 3 
(CIN 3). Full-thickness involvement in the past was called carcinoma in situ 
(CIS) and is now often called grade 3. 
A new classification is now being applied to these lesions. In 1988 the 
National Cancer Institute convened a panel to address the issue of the 
15 
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classification of Papanicolaou (Pap) smears (National Cancer Institute Workshop, 
1989). The panel's goal was to define a uniform terminology for smear reading, 
standards for the adequacy of the smear, and guidelines for tying the results of the 
smear to the clinical management of the patient. The resulting Bethesda 
classification has the underlying philosophy that it is difficult to distinguish 
between lesions caused by human papillomavirus (HPV) and CIN 1; so the two 
types are combined into one category called low-grade squamous intraepithelial 
lesions (LGSIL). Similarly, CIN 2 and 3 lesions are placed in a category called 
high-grade squamous intraepithelial lesions (HGSIL). Lesions that contain 
cells with abnormal nuclear characteristics but without changes suggestive of 
koilocytotic atypia or CIN 1 are classified as atypical squamous cells of 
undetermined significance (ASCUS). The terms LGSIL and HGSIL, although 
designed for use by the cytology community, have been adapted for use in the 
histopathology community. Many institutions now report lesions in the 
following manner: HPV/LGSIL, CIN 1/LGSIL, CIN 2/HGSIL, and CIN 
3/HGSIL. The European community has not embraced the Bethesda 
classification because many believe the lesions should be grouped differently, 
with HPV in a separate category from CIN 1 and 2 and CIN 1 and 2 in a different 
category from CIN 3 and CIS. 
Cervical Cancer 
When malignant cells penetrate the underlying basement membrane of the 
epithelium and infiltrate the stroma, the lesion is considered to be invasive 
cervical cancer, with potential for further growth and for the formation of 
- -
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metastatic deposits. Invasive cervical cancer lesions are also classified in three 
grades: grade 1, or well-differentiated carcinoma; grade 2，or moderately 
differentiated carcinoma; and grade 3，or poorly differentiated carcinoma (Regan 
and Fu, 1983). 
1.1.1 Epidemiology 
Cervical cancer is the second most common cancer among women 
worldwide, following breast cancer. It was estimated that in 1985 about 
437,300 women had a diagnosis of cervical cancer, accounting for 12% of all 
cancers in women (Parkin et al., 1993). Each year, there are in excess of 
200,000 deaths from the disease. When men and women are considered 
together, cancer of the cervix is the fifth most common cancer worldwide, after 
cancers of the lung, stomach, breast and large bowel, accounting for an estimated 
5.7% of all cancers (Parkin et al., 1993 & Pisani et al., 1993). Up to 80% of all 
cervical cancer cases are detected in developing countries. In the United States, 
cervical cancer is the third most common neoplasm of the female genital tract. 
In 1995, 15,800 cases of invasive cervical cancer and 65,000 cases of CIS were 
diagnosed among US women, and about 4800 women died of this neoplasm 
(American Cancer Society, 1995). 
In the last 40 years, incidence and mortality rates for cervical cancer have 
declined in most developed countries (Coleman et a/., 1993). This decline is 
attributed mainly to the introduction of screening with the Pap smear. Despite 
this decreasing trend, cervical neoplasia continues to be the leading cause of 
3 
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death from cancer among women in most developing countries and an important 
health problem in women worldwide, particularly in undeserved populations. 
Furthermore, the declining trend of incidence and mortality that has been 
observed in the United States and other developed countries since the mid-1980s 
seems to be leveling off. 
1.1.1.1 Descriptive Epidemiology 
Geographic Patterns 
Worldwide 
Incidence rates for cervical cancer show a wide geographic variation. 
Parkin DM et al. presents age-adjusted incidence rates of invasive cervical cancer 
from selected cancer registries worldwide (Parkin et al., 1992). A 21-fold 
difference exists between the lowest rate (2.6 per 100,000 women among 
non-Jews in Israel) and the highest rate (54.6 per 100,000 women in Peru). 
Higher incidence rates are reported in developing countries, particularly in Latin 
America and the Caribbean; lower rates are reported in Israel, Kuwait, Finland, 
Spain, China, Canada (British Columbia), and whites in the United States (Parkin 
et al, 1992). The differences between countries may be partially explained by 
differences in health care systems, intensity of screening programs, and exposure 
to major risk factors (Munoz and Bosch, 1989). 
Likewise, incidence and mortality rates for invasive cervical cancer are 
. higher in developing countries (Wingo et al., 1995). Higher mortality rates are 
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observed in Latin America and Eastern Europe, and lower rates are observed in 
western Europe, Canada, and the United States. Data from the World Health 
Organization (WHO) for the period 1988 through 1991 show a large geographic 
variation in mortality for cervical cancer among 46 selected countries. The 
highest age-adjusted mortality rate is observed in Mexico (15.9 per 100,000)，and 
the lowest in Italy (0.9 per 100,000). 
Hong Kong 
In 1995-1996 cancer of the cervix uteri accounted for 5.7% of all newly 
diagnosed cases and 3.8% of all cancer deaths in females. This cancer ranked 
4th for new cancers and for cancer deaths in women. There were 445 newly 
diagnosed cases in 1996，contrary to 498 cases in previous year. Generally, 
cancer of the cervix uteri occurred more frequently in middle age group. The 
rate of increase in incidence curve is declining after the age of 40. Despite 
increasing incidence of cervical cancer in the younger age group, it remains 
predominantly a disease of older women. Over 60% of new cases and 80% of 
deaths occurred in those aged over 50. The average local female has about a 1 
in 60 chance of developing cervical cancer and 1 in 208 chance of dying from 
cancer before the age of 75. 
An obvious decline in age-standardized incidence rate was observed from 
1985-1996. The highest incidence of 18.9 per 100,000 women was recorded in 
1985 and the lowest value of 11.6 was observed in 1996. It represented a 
. decrease in incidence of 38% between 1985 and 1996. An improved 
socioeconomic environment may be responsible. The introduction of screening 
- -
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using Pap smear may be one of the factors. Recent declines in incidence of 
cervical cancer have also been documented in other parts of Asia, e.g. Japan and 
Singapore. 
Regarding the mortality, the overall trend was also noted to be decreasing 
but less obvious than incidence. Age-standardized mortality rates varied from 
3.2 to 5.1 per 100,000 women. 
Trends in Incidence and Mortality 
During the last four decades, incidence and mortality rates for cervical 
cancer have declined in most developed countries. The decline is attributed 
mainly to intensive screening with the Pap smear. In the United States, 
incidence declined by about 70% during this period. Compared with the rate for 
1959 to 1961, the rate of mortality from cervical cancer declined by 63% in the 
Untied States for 1989 to 1991 (American Cancer Society, 1995). Similar trends 
were reported in Western Europe, Canada, Australia, New Zealand, Japan, Hong 
Kong, and Singapore during this period, and slighter declines were seen in 
Eastern Europe and Latin America. 
However, the shift in the incidence of cervical neoplasia (meaning 
premalignant and invasive lesions) among young white US women was first 
identified for CIS. From 1991 to 1995, the estimated number of new CIS cases 
by the SEER program has increased by about 30% (from 50,000 in 1991 to 
65,000 in 1995). Since 1986 the incidence of invasive cancer in white women 
aged under 50 years has been increasing about 3% annually. Similar trends have 
“ - I “ 
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been reported in England and Wales, Canada, Italy, New Zealand, and Australia 
(Brinton, 1992; Ciatto et al., 1995; Munoz and Bosch, 1989). 
The reasons for the recent increasing trend in cervical neoplasia among 
young women are poorly understood and should be interpreted with caution. 
Although these increases in CIS and invasive cancer might be due to an increase 
in the prevalence of HPV infection or to changes in sexual behavior pattern, 
childbearing patterns, oral contraceptive use, and screening and treatment 
practices, other factors, such as changes in coding and registration procedures, 
changes in screening coverage, changes in hysterectomy rates, and changes in the 
proportion of cases classified as "uterus not otherwise specified," need to be 
considered. 
Survival 
The overall 5-year relative survival rate for patients with cervical cancer is 
about 67%; this rate remained constant during the periods of 1970 to 1973 and 
1983 to 1989. Survival is higher for white and younger women; the highest 
survival rates are among white women aged under 50 years, the lowest among 
African-American women aged 50 years and older. Survival rates are high 
(-90%) when the disease is diagnosed at early stages and poor (-13% to 14%) 
when it is diagnosed at advanced stages. 
1.1.1.2 Risk Factors 
• Epidemiologic evidence has long suggested that cervical neoplasia behaves 
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like an sexually transmitted disease (STD). In support of this hypothesis, 
several measures of sexual behavior are consistently associated with an increased 
risk for cervical neoplasia. Risk is higher for women with multiple partners, 
women whose sexual partners are more promiscuous, and women whose first 
sexual intercourse was at an early age (Munoz and Bosch, 1989). These 
characteristics of sexual behavior are considered surrogate measures of a sexually 
transmitted infectious pathogen or pathogens involved in cervical neoplasia. 
Previous studies focused on the etiologic role of several sexually transmitted 
infections, including herpes simplex virus (HSV) type 2 (HSV-2), Chlamydia 
trachomatis, Trichomonas vaginalis, cytomegalovirus, Neisseria gonorrhoeae, and 
Treponema pallidum (Paavonen et al., 1990). Since the mid-1970s, 
experimental, clinical, and epidemiologic evidence has been accumulating on the 
role of some types of HPV in the pathogenesis of cervical neoplasia (Koutsky, 
1991 & Mufioz and Bosch, 1992). 
In addition to these factors, low socioeconomic status, reproductive history, 
smoking habits, oral and barrier contraceptive use, dietary factors, 
immunosuppression, frequency of Pap smears, and characteristics of the male 
sexual partners have been implicated as risk factors for cervical neoplasia 
(Brinton, 1992). Similar risk factors have been associated with both invasive 
and preinvasive lesions. These factors are highly correlated, making it difficult 
to identify independent effects and assess interactions. Moreover, only the most 
recent epidemiologic studies Jhave been able to assess the role of HPV, allowing 
. better control of confounding (Munoz and Bosch, 1992). 
- ^ -
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Characteristics of Sexual Behavior 
Number of Sexual Partners 
Numerous studies have reported an association between cervical neoplasia 
and several indicators of sexual behavior in women and their male sexual partners 
(Brinton, 1992). Number of sexual partners has been a consistent, strong risk 
factor for both perinvasive and invasive lesions of the cervix, and the risk 
increases with greater number of sexual partners (Zaninetti et aL, 1986; Munoz 
and Bosch, 1989; Jones et aL, 1990; Brinton, 1992; Kjaer et al., 1992; Parazzini 
et al., 1992 & Becker e/a/.，1994b). 
Although results from several epidemiologic studies suggest a stronger 
association with preinvasive than with invasive lesions, the facts that preinvasive 
lesions are seen in younger women and that younger women are more likely to 
have a greater number of sexual partners increase the likelihood of detecting such 
an association (Brinton, 1992). 
Results from recent studies, in which control for HPV infection has been 
possible, show a decrease in the strength of the association between number of 
sexual partners and cervical neoplasia, supporting the idea that number of sexual 
partners may be a proxy measurement of an infectious agent causally associated 
with cervical neoplasia (Herrero et al, 1990; Bosch et al, 1992; Koutsky et al., 
1992; Munoz et al., 1993; Schiffman et al., 1993; Becker et al., 1994a & 
Eluf-Neto et al, 1994 & Olseii et al., 1995). 
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Age at First Sexual Intercourse 
The association between cervical neoplasia and age at first sexual 
intercourse has been less consistent. Understanding the independent effect of 
age at first sexual intercourse is difficult because of the high correlation with the 
number of sexual partners. The association between cervical neoplasia and 
early age at first sexual intercourse may indicate a period of higher susceptibility 
of the cervix to carcinogens or a higher likelihood of exposure of longer period of 
exposure to a sexually transmitted agent causally related to the disease. Several 
epidemiologic studies have been shown an independent effect of early age at first 
sexual intercourse on the risk of cervical neoplasia after controlling for the 
number of sexual partners and other potential confounders (Munoz and Bosch, 
1989; Brinton, 1992 & Parazzini et al., 1992)，but other studies have failed to 
show this independent effect (Zaninetti et al., 1986; Jones et al, 1990 & Kjaer et 
al, 1992). Munoz et al (Munoz et al., 1993) and Bosch et al (Bosch et al., 1992) 
observed a statistically significant association between age at first sexual 
intercourse and cervical neoplasia (CIN 3 and invasive cancer) among Colombian 
and Spanish women after adjustment for HPV status and other risk factors, 
including number of sexual partners, education, income, smoking, and oral 
contraceptive use, whereas others found no independent effect (Herrero et al., 
1990; Morrison et al., 1991; Koutsky et al, 1992; Schiffman et al., 1993; Becker 
et al., 1994a; Eluf-Neto et al., 1994 & Olsen et al., 1995) after controlling for 
similar risk factors. Schiffman et al (Schiffman et al., 1993) observed that 
• among HPV-negative women, those with first sexual intercourse before age 17 
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years had 2.4 times higher risk of developing CIN than those whose first 
intercourse was at age 21 years and older; among HPV-positive women, however, 
no association was observed. 
Role of the Male Sexual Partner 
The role of the male sexual partner as a risk factor for cervical neoplasia has 
received less attention. Epidemiologic studies have shown a correlation 
between geographic areas with high rates of cervical cancer and penile cancer and 
a higher risk of cervical neoplasia among women married to men with penile 
cancer. Also, wives of men previously married to a cervical cancer patient have 
a higher risk of cervical neoplasia. Furthermore, male sexual partners of women 
with cervical neoplasia are more likely to have a history of multiple sexual 
partners or sexually transmitted diseases (STDs) (gonorrhea, herpes, genital warts) 
and a higher frequency of visits to prostitutes (Zunzunegui et al., 1986; Munoz 
and Bosch, 1989; Kjaer et al, 1991; Brinton, 1992; Kjaer et al., 1992; Agarwal et 
al., 1993 & Munoz et al., 1993). In contrast, a lower risk of cervical neoplasia 
has been observed among women whose husbands reported more frequent use of 
condoms (Brinton, 1992 & Kjaer et al., 1992). 
The role of male sexual partners as a reservoir of a sexually transmitted 
factor causally related to cervical neoplasia has been established by several 
clinicopathologic studies (Levine et al., 1984; Schneider et al., 1987 & Barrasso, 
1992). Colposcopically detected lesions suggestive of HPV infection have been 
. detected in 53% to 80% of male partners of women with cervical abnormalities 
(Barrasso, 1992). 
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Reproductive Factors 
No consistent relationships between cervical neoplasia and other menstrual 
and reproductive characteristics, such as age at menarche, age at menopause, 
parity, number of spontaneous or induced abortions, age at first pregnancy, age at 
first live birth, age at last birth, number of vaginal deliveries, and number of 
cesarean sections, have been established (Zaninetti et al., 1986; Parazzini et al., 
1989a; Herrero et al., 1990; Jones et al., 1990; Bosch et al.’ 1992; Kjaer et al., 
1992; Parazzini et al., 1992; Munoz et al., 1993; SchifFman et al., 1993; Becker 
et al., 1994a; Eluf-Neto et al., 1994 & Olsen et al, 1995). No association 
between cervical neoplasia and history of cesarean section or abortion has been 
observed after controlling for HPV status and other confounding factors (Herrero 
et al., 1990; Bosch et al, 1992; Munoz et al., 1993 & Becker et al” 1994a). 
An association between parity, or number of live births, and the risk for 
cervical neoplasia was reported in five recent case-control studies after 
controlling for potential confounding factors, including HPV status (Herrero et al., 
1990; Kjaer et al., 1992; Munoz et al., 1993; Schiffman et al., 1993 & Eluf-Neto 
et al., 1994). No association was found for preinvasive lesions (CIN 2 and 3) by 
Becker et al (Becker et al, 1994a) or Olsen et al (Olsen et al., 1995) or for 
invasive cancer by Bosch et al (Bosch et al., 1992). In Denmark, women with 
two or more pregnancies were found to have about an 80% higher risk of CIS 
compared with nulliparous women after adjustment for age, sexual behavior, 
smoking, age at first episode of genital warts, and use of barrier contraceptives 
and intrauterine devices (Kjaer et cd‘, 1992). Schiffman et al (SchifFman et al., 
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1993) observed an increased risk for CIN with increasing parity that persisted 
after controlling for age and HPV status. Women with four or more live births 
had an almost threefold increased risk of CIN compared with nulliparous women. 
Among HPV-negative women, but not HPV-positive women, high parity (four or 
more live births) was significantly associated with CIN. Munoz et al (Munoz et 
al., 1993) observed a twofold increased risk for CIN 3 associated with high parity 
(six or more pregnancies) in Colombian women, but not in Spanish women, after 
controlling for HPV status, age, sexual behavior, and other potential confounders. 
The association between parity and CIN3 persisted when the analysis was 
restricted to cases and controls who were HPV positive, although the trend with 
increasing number of pregnancies was not statistically significant. Eluf-Neto et 
al (Eluf-Neto et al., 1994) (in Brazil) and Herrero et al (Herrero et al., 1990) 
(studying four Latin American countries) observed fivefold (among women with 
> 10 pregnancies) and twofold (among women with > 12 live births) increased 
risks for invasive cancer, respectively, after controlling for HPV infection and 
other potential confounding factors. Although the biologic mechanism for this 
association is unclear, it is suggested that suppression of the immune system or 
hormonal changes during pregnancy may increase the susceptibility of infection 
to HPV or may increase the oncogenic capabilities of the virus (Kjaer et al., 
1992). Other recent studies have failed to support this association with both 
CIN (Becker et al., 1994a & Olsen et al, 1995) and invasive cancer (Bosch et al., 
1992). 
• An increasing finding by Bosch et al (Bosch et al., 1992) was a strong 
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association between invasive cervical cancer and early age at first birth; this 
association appeared to be independent of early age at first sexual intercourse, 
HPV status, additional childbirths after age 22 years, and other potential 
confounding factors; no association with parity was observed. Despite the high 
correlation between early age at first intercourse and early age at first pregnancy 
in the study population, by restricting the analysis to women who first had sexual 
intercourse before age 22 years, the authors identified a fourfold increased risk 
for invasive cancer among women who had one or more childbirths before age 22. 
Another interesting finding in a recent study by Becker et al (Becker et al., 1994a) 
was the association between the number of vaginal deliveries and high-grade 
dysplasia (CIN 2 and 3); this association persisted after adjustment for potential 
confounders, including HPV status, ethnicity, and other sexual and reproductive 
characteristics. Women who had one or more vaginal deliveries had a 70% 
higher risk for CIN than women without history of vaginal delivery. There is no 
clear biologic mechanism to support this association, although repeated trauma to 
the cervix during childbirth has been suggested. 
Smoking Habits 
Several epidemiologic studies have provided evidence supporting an 
association between cigarette smoking and CIN and invasive cervical cancer 
(Wilkenstein, 1990). Most studies have shown a twofold increased risk for 
cervical neoplasia among smokers and a dose-response relationship with the 
duration and intensity of smoking (Wilkenstein, 1990 & Brinton，1992). After 
adjustment for potential confounders, including characteristics of sexual behavior, 
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a decreased but still significant independent effect has persisted. In addition to 
the epidemiologic data favoring an association between cigarette smoking and 
cervical neoplasia, several biochemical studies have reported the presence of 
nicotine, cotinine, and mutagens in the cervical mucus of women actively or 
passively exposed to tobacco smoke (Schiffman et al., 1987 & Hellberg et al., 
1988). In addition, molecular evidence of DNA damage has been demonstrated 
in cervical tissue and exfoliated cells of women who smoke (Simons et al., 1995). 
The prevalence of DNA adducts in cervical samples from smokers is statistically 
significantly higher than that in samples from nonsmokers (Cuzick et al., 1990b; 
Simons et al., 1993 & Simons et al., 1995). These studies have provided 
biologic plausibility for the association and have suggested three possible 
mechanisms of carcinogenesis: (1) a direct carcinogenic effect, (2) a 
cocarcinogenic effect, or (3) a local immunosuppressive effect. 
Oral and Barrier Contraceptive Methods 
An association with oral contraceptives has been reported for preinvasive 
and invasive cervical lesions, although recent studies have suggested a higher risk 
for severe preinvasive lesions (HGSIL) than for less severe preinvasive lesions 
(atypia and LGSIL) and invasive lesions (Harris et al., 1980; Negrini et al., 1990 
& Brinton, 1992). An increased risk for cervical neoplasia in patients with 
long-term oral contraceptive use has been supported by cohort and case-control 
studies; this increased risk remains after controlling for several risk factors, 
s. 
including sexual behavior and history of Pap smear screening. The results of 
more recent epidemiologic studies that control for HPV status continue to be 
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conflicting (Brinton et al., 1990; Negrini et al., 1990; Morrison et al., 1991; 
Bosch et al., 1992; Koutsky et al., 1992; Schiffman et al., 1993; Becker et al.’ 
1994a; Eluf-Neto et al., 1994 & Olsen et al., 1995). Most studies have failed to 
show an association between cervical neoplasia and different measurements of 
oral contraceptive exposure (Brinton et al, 1990; Morrison et al., 1991; Bosch et 
al, 1992; Koutsky et al., 1992; Munoz et al., 1993; Schiffman et al” 1993 & 
Olsen et al., 1995), but two studies showed opposite results among women with 
high-grade lesions (Negrini et al., 1990 & Becker et al,, 1994a), and another 
showed an increased risk of borderline significance among women with invasive 
cancer. Becker et al (Becker et al, 1994a) observed a protective effect against 
high-grade dysplasia in women who had ever used oral contraceptives (OR 0.4, 
95% CI 0.2-0.9) and among former users (OR 0.4, 95% CI 0.1-0.9). In contrast, 
Negrini et al (Negrini et al, 1990) found a statistically significant increased risk 
of HGSIL among women using oral contraceptives for 5 or more years (OR 4.6, 
95% CI 1.1-18.0) and an increased risk of borderline significance among women 
who had ever used oral contraceptives (OR 2.7，95% CI 0.8-9.5), but no 
association was observed for atypia or LGSIL. Similarly, Eluf-Neto et al 
(Eluf-Neto et al., 1994) observed a 2.5-fold increased risk of borderline 
significance (95% CI 0.9-7.3) for invasive cancer. 
Several epidemiologic studies reported a lower risk of disease among users 
of barrier contraceptive methods (condom or diaphragm), and an inverse 
relationship with number of years of use was found after adjustment for 
. confounding factors, supporting a sexually transmitted cause of cervical neoplasia 
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(Wright et al., 1978; Harris et aL, 1980; Munoz and Bosch, 1989; Jones et al., 
1990 & Brinton，1992). Similar results with length of use have been reported 
for CIN and invasive cancer (Parazzini et al., 1989b), but a protective effect from 
specific barrier methods has not been consistently found (Wright et al., 1978; 
Celentano et al, 1987; Parazzini et a/., 1989b; Hildesheim et al., 1990; Jones et 
al., 1990; Kjaer et al., 1990; Munoz et al., 1993 & Becker et al., 1994a). Some 
studies report a decreasing risk of preinvasive lesions with diaphragm effect 
associated with condom use has been less conclusive (Parazzini et al., 1989b; 
Jones et al, 1990; Munoz et al., 1993 & Becker et al., 1994a). 
Dietary Factors 
Nutritional factors have been implicated in 60% of cancers in women and in 
40% of cancers in men (Schneider and Shah, 1989). Several lines of evidence 
suggest that some nutrients may have a protective effect against cervical 
neoplasia, particularly vitamin A, carotenoids, vitamin C, vitamin E, and folic 
acid. The association between vitamin A intake and cervical neoplasia is 
hypothesized based on the relationship of vitamin A and other epithelial tumors, 
mainly squamous cell carcinomas. Vitamin A is capable of reverting metaplastic 
changes in bronchial epithelium, providing a biologic basis for the association 
with cervical neoplasia (Schneider and Shah, 1989). Vitamin C plays a role in 
the maintenance and protection of the normal epithelium against carcinogens. 
Folic acid functions as a coenzyme in the metabolism of single-carbon 
V 
compounds, such as nucleic acid synthesis and amino acid metabolism 
(Schneider and Shah, 1989). It has been hypothesized that subclinical folate 
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deficiency may act as a cofactor in the integration of the HPV genome into host 
DNA (Butterworth, 1992). 
In recent epidemiologic studies in which control of potential confounding 
factors has been more adequate, findings of an association between dietary or 
serum/plasma levels of nutrients and cervical neoplasia remain inconclusive. 
Some studies have shown a lower risk of cervical neoplasia associated with 
dietary intake and serum levels of carotenoids (particularly beta-carotenes and 
lycopene), vitamin C, folic acid, and gamma-tocopherol after controlling for 
confounding factors (Cuzick et al., 1990a; Herrero et al., 1991; Potischman et al., 
1991b; VanEenwyk et al., 1991; VanEenwyk et al., 1992; Batieha et al., 1993 & 
Liu et al., 1993), whereas other investigators found no association (Ziegler et al, 
1990; Ziegler et al., 1991 & Potischman, 1993). Most studies have not found an 
association between retinol and risk of cervical neoplasia (Potischman, 1993). 
Folate levels appear to be more consistently associated with the risk for 
premalignant cervical lesions than with the risk for invasive lesions (VanEenwyk 
et al., 1992 & Potischman, 1993)，and red blood cell folate.levels have been 
considered a better predictor of risk of cervical neoplasia than dietary or serum 
folate levels (Potischman et al., 1991a; Ziegler et al., 1991; VanEenwyk et al,, 
1992 & Potischman, 1993). An interaction between red blood cell folate levels 
with HPV-16 positivity, cigarette smoking, and parity has been suggested 
(Butterworth et al, 1992). This interaction effect is consistent with current 
knowledge of the role of folate j n carcinogenesis. Further studies addressing the 
. interaction between these nutrients and other risk factors such as smoking and 
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HPV are needed, as are studies that examine the effects of nutrient intake among 
different ethnic and racial groups. 
Human Papilloma Virus (HPV) 
The hypothesis that cervical neoplasia behaves like a STD has stimulated the 
search for a sexually transmitted etiologic agent. In the last decade, the search 
for a sexually transmitted cause of cervical neoplasia has focused on the role 
certain types of HPV. The hypothesis that HPV infection is associated with 
cervical neoplasia was proposed by zur Hausen in 1976 (zur Hausen, 1977). 
Evidence supporting this association includes animal models documenting the 
oncogenicity of animal and human papillomaviruses, demonstration of certain 
types of HPV in genital warts and koilocytotic atypia of the cervix, detection of 
HPV antigens in CIN lesions, and demonstration of HPV DNA in derived cell 
lines and CIN and cervical cancer lesions (zur Hausen, 1977; Koutsky et al., 1988; 
Bosch and Munoz, 1989 & Reeves et al., 1989). 
Of the more than 100 types of HPV that have been described today, more 
than 35 are associated with anogenital disease and 20 or more are associated with 
cancer (Bosch et al., 1995). The most common HPV types detected in cervical 
lesions are those classified as high-risk HPV types, including types 16，18，45, 
and 56, and intermediate-risk types, including types 31, 33，35, 51, 52, and 58. 
Overall, HPV DNA has been detected in more than 79% of specimens of women 
with definite cervical disease (Lorincz et al., 1992). The prevalence of HPV 
. infection is higher in women with cervical carcinoma, intermediate in women 
with CIN, and lower among women with cytologically normal tissue. The 
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prevalence of HPV increases with the sensitivity of the detection technique 
(higher prevalence estimates are observed with the use of PCR) and with the use 
of repeat testing (up to fivefold higher prevalence estimates are observed) 
(Schneider et al., 1992). In a recent international study, HPV DNA was detected 
in 93% (range 75%-100%) of cancer specimens collected in 22 countries and 
analyzed by the PCR technique (Bosch et al.’ 1995). Similarly, HPV DNA was 
detected by PCR in up to 94% of women with preinvasive lesions (CIN) 
(Morrison et al.., 1991; Munoz et al., 1993; Schiffman et al., 1993; Becker et al, 
1994a & Olsen et al., 1995) and in up to 46% of women with cytologically 
normal tissue (Schneider and Koutsky, 1992). 
Intermediate- and high-risk types of HPV have been identified in about 77% 
of HGSIL (CIN 2 and 3) and in 84% of invasive lesions (Lorincz et al., 1992). 
HPV-16 is by far the most prevalent HPV type in women worldwide, being 
present in about 50% of HGSIL and cancer (Lorincz et al., 1992; Schneider and 
Koutsky, 1992 & Bosch et al., 1995). In addition, it is the most commonly 
identified HPV type in cytologically normal women (Lorincz et al., 1992). 
Because of the high prevalence of HPV infection in both cytologically normal 
and cytologically abnormal women worldwide, it is hypothesized that HPV may 
be a necessary but not sufficient cause for the development of cervical neoplasia. 
Similar results are reported for cervical cancer in recent epidemiologic 
studies. Munoz et al (Munoz et al., 1992a) observed a 50-fold increased risk in 
� 
Spain (OR 46.2, 95% CI 18.5-115.1) in HPV-positive women and a 16-fold 
increased risk in Colombia (OR 15.6，95% CI 6.9-34.7), and Eluf-Neto et al 
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(Eluf-Neto et al., 1994) in Brazil detected an OR of 37.1 (95% CI 19.6-70.4). 
All recent epidemiologic studies have consistently shown a stronger association 
of cervical neoplasia with high-risk HPV types (particularly HPV-16), with 
multiple HPV-type infections, with higher viral loads, and with more severe 
lesions (Munoz and Bosch, 1992). In addition, HPV-positive women are at 
higher risk for progression from LGSIL to HGSIL, particularly those positive for 
HPV-16 and -18 (Koutsky et al., 1992 & Mufioz and Bosch, 1992). 
Summary 
Cervical neoplasia continues to be a major health problem worldwide. 
Higher incidence and mortality rates are observed in developing countries. In 
more developed countries, a significant decline in incidence and mortality has 
been observed in the last 40 years, which has been attributed to the introduction 
of screening programs. In several developed countries, however, a reversed 
trend in the incidence of invasive cervical cancer and CIS among young women 
was recently detected. This reversed trend is attributed to changes in sexual 
behavior and appears to follow a rapid increase in the rates of CIN, which began 
in the mid-1980s. 
Current epidemiologic data support a strong role of HPV infection in the 
etiology of cervical neoplasia. This association satisfies all the criteria for 
causality in epidemiologic research: strength, consistency, and specificity of the 
association, dose-response and temporal relationship, and biologic plausibility 
. (Munoz and Bosch, 1992). Furthermore, recent studies have found that HPV 
infection appears to explain many of the established risk factors for cervical 
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neoplasia, including sexual behavior and cigarette smoking. Although HPV is 
the most important risk factor for cervical neoplasia, the participation of other 
cofactors seems to be necessary for the development of disease (Lorincz et al, 
1992 & Schiffman, 1992). The difference between the high prevalence of HPV 
infection (11% to 80%) in young healthy women and the low incidence of 
cervical neoplasia, as well as the low rate of progression of untreated CIN lesions, 
supports the hypothesis that HPV may be a necessary but insufficient factor for 
cervical neoplasia. The introduction of more accurate and effective methods for 
the detection of HPV infection will improve the opportunity to conduct larger 
epidemiologic studies to assess the role of other cofactors and the interaction 
between HPV and other risk factors, particularly smoking habits, hormonal 
factors, and dietary factors. The role of HPV persistence in the progression of 
cervical neoplasia and the determinants of HPV persistence need further 
evaluation. Moreover, the impact of recent trends that affect these risk factors 
on the occurrence of cervical neoplasia deserves future attention (Brinton, 1992). 
1.1.2 Pathology 
1.1.2.1 Macroscopic Appearance 
The cervix is the lower third of the uterus. It is roughly cylindrical in shape, 
projects through the upper, anterior vaginal wall and communicates with the 
vagina through an orifice called the external os. Cancer of the cervix may 
originate on the vaginal surface or in the canal. 
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The macroscopic appearance of cervical cancer is variable. The lesions 
may be exophytic, endophytic, or ulcerative. Exophytic tumors are the most 
common; they arise on the exocervix and grow toward the vaginal canal. These 
lesions are usually squamous cells in origin. Endophytic tumors arise in the 
endocervix, are most often adenocarcinomas, and tend to distend the cervix and 
the endocervical canal. A third variety is the ulcerative type, which replaces the 
cervix and the upper third of the vagina with a necrotic crater. 
1.1.2.2 Symptoms and Diagnosis 
Most women with cervical cancer fail to develop symptoms until late in the 
disease. At that stage, most patients are asymptomatic; may have pelvic pain 
and abnormal vaginal bleeding, especially after intercourse; may have irregular 
menses (periods) or foul vaginal discharge. New bleeding may also appear in 
women at the time of the menopause. Patients with advanced disease may have 
weight loss, or obstructive uropathy. 
Early detection is the key to reducing the mortality rate for cervical cancer. 
The standard screening test is the Pap smear, named for Dr. George Papanicolaou, 
an anatomist and cytologist. The cervical epithelium normally sheds its 
superficial cells, and a sample of cells scraped or brushed from the epithelial 
surface can be examined for abnormal or cancerous cells. The American Cancer 
Society recommends yearly Pap tests at ages 20 and 21, followed by smears at 1-
V 
to 3-year intervals until age 65. 
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Preinvasive Disease 
To be suitable for screening, a disease must pass through a preclinical phase 
during which it is undiagnosed but detectable. It is believed that most squamous 
cell carcinomas begin as dysplastic lesions and progress to CIS and then to 
invasive disease over a variable time period. 
Several studies have investigated the natural history of CIN. In these trials, 
6086 patients with CIN and 353 patients with CIS were enrolled and underwent 
cytologic analysis, colposcopic observation, and biopsy only (Mitchell et al., 
1994). In some series, follow-up was for 20 years. Of patients with CIN 
grades 1 to 3, 14% progressed to CIS and 1.4% to invasive cancer. Of those 
with CIS, 36% progressed to invasive cancer. Clearly, CIS lesions are much 
more likely to progress to invasive cancer than CIN lesions, and they must be 
evaluated and treated more aggressively than lower grade lesions. Biologic 
markers or technologies that identify high-grade lesions and distinguish them 
from low-grade lesions would thus be highly useful. 
Metastatic Spread Pattern 
Invasive cervical carcinoma has two predominant spread patterns: direct 
extension and lymphatic dissemination. Cervical cancer spreads from the cervix 
to adjacent tissues, especially to the upper vagina and the parametria! tissues 
(cardinal and uterosacral ligaments). The tumor may also involve the pelvic 
� 
sidewall. The lymphatic spread pattern of cervical cancer is fairly predictable 
« 
and proceeds in a stepwise fashion. Malignant cells spread via paracervical 
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lymphatic channels into the pelvic node chains associated with the obturator, 
internal iliac, and external iliac vessels. The cells then spread cephalad to the 
common iliac chain and the para-aortic lymph nodes. 
Clinical-diagnostic staging 
Staging of cervical cancer is based on clinical evaluation; therefore, careful 
clinical examination should be performed in all cases. The following 
examinations are permitted: palpation, inspection, colposcopy, endocervical 
curettage, hysteroscopy, cystoscopy, proctoscopy, intravenous urography, and 
X-ray examination of the lungs and skeleton. Suspected bladder or rectal 
involvement should be confirmed by biopsy and histologic evidence. 
Conization or amputation of the cervix is regarded as a clinical examination. 
Invasive cancers so identified are to be included in the reports. 
1.1.2.3 Staging Classification 
Stage 0 comprises those cases with full-thickness involvement of the 
epithelium with atypical cells but with no signs of invasion into the stroma. 
The diagnosis of both Stage lal and Ia2 should be based on microscopic 
examination of removed tissue, preferably a cone biopsy, which must include the 
entire lesion. The depth of invasion should not be > 5 mm taken from the base 
of the epithelium, either surface or glandular, from which it originates. The 
second dimension, the horizdntal spread, must not exceed 7 mm. Vascular space 
‘ involvement, either venous or lymphatic, should not alter the staging, but should 
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be specifically recorded because it may affect treatment decisions in the future. 
Larger lesions should be staged as lb. As a rule, it is impossible to clinically 
estimate if a cancer of the cervix has extended to the corpus. Extension to the 
corpus should therefore be disregarded. 
A patient with a growth fixed to the pelvic wall by a short and indurated, but 
not nodular, parametrium should be allotted to Stage lib. It is impossible, at 
clinical examination, to decide whether a smooth and indurated parametrium is 
truly cancerous, or only inflammatory. Therefore, the case should be placed in 
Stage III only if the parametrium is nodular to the pelvic wall or if the growth 
itself extends to the pelvic wall (Table 1.1.2.3). 
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Table 1.1.2.3 Carcinoma of the Cervix Uteri: FIGO Nomenclature (1994) 
Stage 0 Carcinoma in situ, cervical intraepithelial neoplasia Grade III. 
Stage I The carcinoma is strictly confined to the cervix (extension to the 
corpus would be disregarded). 
Stage la Invasive carcinoma which can be diagnosed only by microscopy. 
All macroscopically visible lesions - even with superficial 
invasion - are allotted to Stage lb carcinomas. Invasion is limited 
to a measured stromal invasion with a maximal depth of 5.0 mm 
and a horizontal extension of not > 7.0 mm. Depth of invasion 
should not be > 5.0 mm taken from the base of the epithelium of 
the original tissue - superficial or glandular. The involvement of 
vascular spaces - venous or lymphatic - should not change the 
stage allotment. 
Stage lal Measured stromal invasion of not >3.0 mm in depth and 
extension of not > 7.0 mm. 
Stage Ia2 Measured stromal invasion of > 3.0 mm and not > 5.0 mm with an 
extension of not > 7.0 mm. 
Stage lb Clinically visible lesions limited to the cervix uteri or preclinical 
cancers greater than Stage la. 
Stage Ibl Clinically visible lesions not > 4.0 cm. 
Stage Vol Clinically visible lesions > 4.0 cm. 
Stage II Cervical carcinoma invades beyond the uterus, but not to the 
pelvic wall or to the lower third of the vagina. 
Stage Ila No obvious parametrial involvement 
Stage lib Obvious parametrial involvement 
Stage III The carcinoma has extended to the pelvic wall. On rectal 
examination, there is no cancer-free space between the tumour and 
the pelvic wall. The tumour involves the lower-third of the 
vagina. All cases with hydronephrosis or nonfunctioning kidney 
are included, unless they are known to be due to other cause. 
Stage Ilia Tumour involves lower-third of the vagina, with no extension to 
the pelvic wall 
(Continued) 
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Table 1.1.2.3 (Continued) 
Stage Illb Extension to the pelvic wall and/or hydronephrosis or 
nonfunctioning kidney 
Stage IV The carcinoma has extended beyond the true pelvis, or has 
involved (biopsy-proven) the mucosa of the bladder or rectum. A 
bullous oedema, as such, does not permit a case to be allotted to 
Stage IV. 
Stage IVa Spread of the growth to adjacent organs 
Stage IVbSpread to distant organs 
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1.1.2.4 Histopathology 
Cervical cancer is believed to result from the progression of milder epithelial 
abnormalities called dysplasia of cervical intraepithelial neoplasia. A new 
cytologic classification system, which combines clinically similar diagnoses into 
broad categories, including low-grade and high-grade squamous intraepithelial 
lesions, has also recently been proposed. The gradient from the milder to more 
severe grades of neoplasia is characterized by increasing nuclear atypia and 
failure of cellular differentiation in progressively more superficial levels of 
epithelium, with carcinoma in situ representing fUll-thickness abnormality. 
The epithelial abnormalities of the cervix from a continuous spectrum of one 
disease process: an infinitely variable spectrum in which each degree of 
abnormality merges imperceptibly in the next. 
The Bethesda System (TBS) for reporting cervical and vaginal diseases has 
adopted a two-tier system for cytological reporting of cervical epithelial 
abnormalities (Solomon, 1989; Solomon, 1991 & Luff et al., 1992). This 
system divides the epithelial abnormalities into high-grade and low-grade 
squamous intraepithelial lesions, the high-grade lesions being CIN 2 and CIN 3 
and the low-grade lesions CIN 1 and wart virus infection. 
The histologic features on which a diagnosis of CIN is based relate to 
differentiation, nuclear abnormalities and mitotic activity. 
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CIN 1 
Nuclear abnormalities are mild and are most marked in the basal one-third 
of the epithelium although some nuclear abnormality persists to the surface; were 
this no so, a cytologic diagnosis would not be possible. Mitotic figures are 
present, but are not numerous and are confined to the basal one-third of the 
epithelium. The upper two-thirds of the epithelium shows good differentiation. 
CIN 2 
Nuclear abnormalities are more severe than in CIN 1 and nuclei showing 
more abnormality are found higher in the epithelium. Mitotic figures, which 
may be abnormal, are seen in the basal two-thirds of the epithelium. The upper 
half of the epithelium shows maturation and differentiation, with some nuclear 
atypia persisting to the surface. 
CIN 3 
Marked nuclear abnormalities are present throughout the whole thickness of 
the epithelium, with mitotic figures found at all levels of the epithelium. 
Abnormal configurations may be frequent. Maturation and differentiation are 
either completely absent or confined to the superficial one-third of the epithelium. 
Microinvasive carcinoma 
The concept of microinvasive carcinoma was introduced by Mestwerdt in 
� 
1974 and the term was used to describe invasive lesions extending not more than 
5 mm into the cervical stroma, in the belief that the small lesions had a much 
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better prognosis than the reminder of Stage I lesions (Mestwerdt, 1951). A 
diagnosis of microinvasive carcinoma should characterize a tumor that is of 
measurable size and locally invasive, but nevertheless has negligible potential for 
metastasis. Unfortunately, information is not available for such a diagnosis to 
be precisely defined at present. 
Currently there are two sets of criteria for separating microinvasive 
squamous cell carcinoma from more deeply invasive tumors. According to the 
International Federation of Gynecology and Obstetrics (FIGO), a stage lA tumor 
of microinvasive squamous cell carcinoma (MICA) is a tumor with a depth of 
invasion of 5 mm or less taken from the base of the epithelium, either surface or 
glandular, from which it originates and with a horizontal extent of 7 mm or less 
(Wright et al., 1994). Vascular space invasion is noted, if present, but it does 
not in itself exclude a tumor from being placed in the microinvasive category. 
The fact that some patients with stage lA tumors as defined by FIGO have had 
lymph node metastases prompted the Society of Gynecological Oncologists 
(SGO) in the United States to propose a more restricted set of criteria for MICA 
(Wright et al, 1994). According to the SGO, a microinvasive lesion is one in 
which the neoplastic epithelium invades the stroma in one or more places to a 
depth of 3 mm or less below the basement membrane of the epithelium from 
which it originates and in which lymphatic or blood vascular invasion is not seen 
(Creasman, et al” 1985). According to the SGO, MICA lesions have virtually 
no potential for either metastases or recurrence. Therefore, the SGO criteria 
appear to be more appropriate than the FIGO criteria for guiding clinical 
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management (Wright et al., 1994). 
Invasive carcinoma 
Squamous cell carcinoma, which is composed almost entirely of squamous 
cells, represents about 60% to 80% of the invasive carcinomas of the cervix 
(Wright et al., 1994)，while the various types of adenocarcinoma making up a 
further 20 to 40% of the total. Occasional tumor cells containing mucin can be 
demonstrated by special stains. Nuclear atypia and mitotic figures may be 
prominent. For microscopic features, squamous cell carcinomas may be 
subdivided histologically according to cell type (Table 1.1.2.4a) and histological 
grade (Table 1.1.2.4b). Keratinizing, non-keratinizing, verrucous, warty 
(condylomatous), papillary and lymphoepithelioma-like carcinoma are the 
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Table 1.1.2.4a Histologic Types of Cervical Carcinoma 

















Glassy cell carcinoma 
Adenoid cystic carcinoma 
Adenoid basal carcinoma 
Carcinoid tumor 
Small cell carcinoma 
Undifferentiated carcinoma 
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Table 1.1.2.4b Histopathologic Grades of Cervical Carcinoma 
Grade I Well-differentiated squamous cell cancer that is composed of 
sheets and cords of cells with abundant acidophilic cytoplasm, 
clearly visible intercellular bridges and often with the production 
of variable amounts of keratin. 
Grade II Moderately differentiated squamous cell cancer, characterized by 
masses and couds of spindle-shaped squamous cells with 
elongated nuclei and scant cytoplasm. They are no intercellular 
bridges and little keratin formation. 
Grade III Poorly differentiated squamous cell cancers have a rapid growth 
rate, with numerous mitoses and cells with closely crowded nuclei 
and scant cytoplasm. 
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1.2 Microsatellite Instability (MSI) 
1.2.1 Microsatellite 
In the chromosomes of eukaryotes, certain base sequences are repeated 
many times in the haploid chromosome complement, sometimes as many as a 
million times. DNA containing such repeated sequences, called repetitive DNA, 
often represents a major component (20 to 50 percent) of the eukaryotic genome. 
Most of the structural genes (genes coding for proteins or RNA molecules) 
are single-copy sequences. The genes for histones, rRNA molecules, and 
ribosomal proteins, all gene products that are present in the cell in large quantities, 
are exceptions; these are redundant (present in moderately repetitive DNA) genes. 
Many genetics have postulated that most other moderately repetitive sequences 
may be involved in the regulation of gene expression. Their interspersion with 
single-copy sequences, and thus their location adjacent to structural genes, is 
certainly consistent with a regulatory role. Another important group of 
moderately repetitive DNA sequences are the transposable genetic elements that 
can move from one location in a chromosome to another or even to a different 
chromosome. The transposability of these moderately repetitive sequences has 
led to much speculation about their possible involvement in the regulation of 
gene expression during development and their roles in the evolution of eukaryotic 
genomes. These transposable elements are responsible for a surprisingly large 
number of the naturally occurring mutations in eukaryotic organisms. 
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The function(s) of highly repetitive DNA-most, if not all, of which is located 
in genetically inactive heterochromatic regions of chromosomes-is completely 
unknown. Postulated functions for highly repetitive DNA include (1) structural 
of organizational roles in chromosomes; (2) involvement in chromosome paring 
during meiosis; (3) involvement in crossing over or recombination; (4) protection 
of important structural genes, like histone, rRNA, or ribosomal protein genes; (5) 
a repository of unessential DNA sequences for use in the future evolution of the 
species; and (6) no function at all-just junk DNA that is carried along by the 
processes of replication and segregation of chromosomes. The validity of any 
of these postulated roles remains to be established. 
"Microsatellite" is now the commonest term used to describe tandem repeats 
of short sequence motifs (no more than six bases long), which is arranged head-to 
tail without interruption by any other base or motif. Microsatellites have been 
detected within the genomes of every organism so far analysed, and are often 
found at frequencies much higher than would be predicted purely on the basis of 
base composition. They may be highly polymorphic, especially if long and 
uninterrupted, and they are therefore useful genetic markers. The functional 
significance of such sequences is still unknown although they are sometimes 
found within exons and have been associated with diseases. Microsatellites 
appear to be more or less uniformly distributed across eukaryotic genomes, but 
are under-represented in coding regions, and perhaps telomeres. Repeats of 
poly(A)/poly(T) are the most common microsatellites in all genomes. The 
‘ dinucleotide repeats are estimated to be the most frequently occurring 
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microsatellites, with an incidence of at least 1 in every 100,000 bp (Lothe, 1997). 
Each microsatellite contains multiple repetitive nucleotide sequences that 
are relatively constant in normal cells but vary in length in certain tumors. Even 
though microsatellite variations might not affect the phenotype of the cell, they 
are by definition mutations. Genetic and other studies suggest that 
slipped-strand mispairing during replication is the predominant mechanism of 
mutation of microsatellites, but recently an increasing amount of circumstantial 
evidence has also implicated recombination. 
However, microsatellites are inherited and unique to each individual, and 
normally have a low inherent mutation rate (Weber et al, 1989; Hearne et al.’ 
1992). Because of the recent development of highly informative markers, 
specifically for tandem repeats (Weissenbach et al., 1992)，it became exceedingly 
helpful to evaluate the genomic instability in tumor. 
1.2.2 Mismatch Repair 
More recently, it has been appreciated that the Mismatch Repair (MMR) 
System plays an important role in preventing the development of human cancers. 
Each time a cell divides, the DNA is copied so that both cells receive a complete 
set of the genetic code. Although DNA synthesis occurs with high fidelity, it is 
estimated that spontaneous errors (mutations) occur about once every million 
bases. In addition, in nondividing cells, mutations may arise because of 
endogenous processes such as methylation and deamination and because of 
exposure to mutagens such as those in tobacco smoke. During DNA replication, 
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a class of genes (MMR genes) are able to repair much of this genetic damage, 
which recognize mismatched base pairs then excise and replace them with the 
correct nucleotides, such as misincooporated bases, nucleotide insertions and 
deletions (Modrich, 1991). 
Discrimination against replication errors first occurs as a multiprotein 
replication machine (MMR system) correctly polymerizes nucleotides at a 
growing replication fork. If a mistake is made, it may be excised prior to further 
chain elongation by an associated 3' to 5' exonuclease (proofreading). Errors 
that escape proofreading may be corrected by post-replication mismatch repair, 
which selectively removes errors from the newly synthesized strand. If these 
mistakes are not corrected during replication, the newly synthesized strand can be 
repaired after replication, using the parental strand as a template. These MMR 
systems are able to repair much of the genetic damage, but some mutations elude 
this surveillance system. The rate at which critical mutations occur in cells may 
be accelerated if the MMR genes themselves have undergone inactivating 
mutations. 
1.2.3 Microsatellite Instability (MSI) 
Microsatellite repeat alterations are the result of slippage due to strand 
misalignment during DNA replication and are referred to as microsatellite 
instability (MSI) (Richards & Sutherland, 1994). It is characterised by the 
accelerated accumulation of single nucleotide mutations and alterations in the 
length of simple, repetitive microsatellite sequences that occur uniquitously 
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throughout the genome (Claij & te Riele, 1999). These errors are thought to 
result from a defect in the MMR system. When MMR is defective, expansion or 
contraction of repetitive sequences at microsatellite regions frequently occurs 
during DNA replication. Tumors with MMR deficiency demonstrate a large 
number of characteristic mutations throughout the genome, a phenomenon that 
has been termed "microsatellite instability" (Thibodeau et al., 1993), the 
"replicative error" phenotype (Aaltonnen et al.’ 1993) or "ubiquitous somatic 
mutations" (lonov et al, 1993). 
MSI was initially described in the familial cancer syndrome, hereditary non 
polyposis colonic cancer (HNPCC) in 1993 (Peltomaki et al., 1993 & Risinger et 
al., 1993). Three laboratories independently recognized that ubiquitous 
mutations could be found in a small proportion of colorectal cancers and that this 
abnormality was present in nearly all tumors from patients with HNPCC 
(Aaltonnen et al, 1993; lonov et al., 1993 & Thibodeau et al., 1993). The type 
of mutation seen in these tumors represented a change in the length of repetitive 
sequences, termed "microsatellites", which have an unknown function in DNA 
but are extremely common. It was immediately recognized by geneticists who 
had worked on yeast and bacterial systems that these mutations represented 
defective DNA MMR, and it was quickly demonstrated that HNPCC could be 
attributed to germ-line mutations that inactivated one of the DNA MMR genes. 
Cell lines with defective DNA MMR were identified, and these were found � 
to have MSI and inactivating mutations in the DNA MMR genes (Parsons et al., 
1993). It was recognized that a deficiency in this homeostatic mechanism 
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would permit the accumulation of mutations at a higher than normal rate, and it 
was assumed that this might be the mechanism by which tumors would occur at 
an early age in HNPCC. Four of the isolated human mismatch-repair genes 
{hMSH2, hMLHl, hPMSI, hPMS2) are mutated in the germline of 
hereditary-non-polyposis-colorectal-cancer (HNPCC) patients, and mutations in 
these genes are believed to be the underlying cause of the observed phenotypic 
instability both in sporadic and in familial tumors (Fishel et al., 1993; Leach et a!., 
1993; Bronner et al., 1994; Papadopoulos et al., 1994; Nicolaides et al., 1994; 
Borresen et al, 1995; Liu et al, 1995b). 
About 60% of HNPCC cases are linked to a locus on chromosome 2p in 
genetic studies (Aaltonen et al, 1993 & Peltomake et al., 1993). It is because 
this locus is not subject to loss of heterozygosity. It is presumed that it does not 
encode tumor suppressor; rather, it was suspected that the aberrant factor is 
involved in replication (Aaltonen et al., 1993). However, the chromosome 2p 
HNPCC protein was soon identified as a homolog of the bacterial MutS and S. 
cererisiae MSH proteins involved in MMR, and was named hMSH2 (human mut 
s homolog) (Fishel et al., 1993; Leach et al., 1993). Different HNPCC families 
with linkage to this locus, as well as some patients with sporadic colorectal 
cancer, carry different heterozygous germline mutations in hMSH2, and at least 
some colorectal tumors have an additional somatic mutation (Leach et al, 1993). 
HMSH2 was previously identified as a G/T mismatch binding protein, GTBP 
(Palombo et al., 1994).�Further genetic studies showed that about 30% of 
• HNPCC cases are linked to another locus, this on chromosome 3p (Lindblom et 
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al, 1993), a locus which was soon identified as encoding another MMR 
homology hMLHl is highly homologous to the bacterial MutL and yeast MLH 
proteins, and HNPCC families carry heterozygous mutations in hMLHl (Bronner 
et al., 1994 & Papadopoulos et al, 1994). Additional HNPCC families are 
likely to deficient in other MMR proteins (Papadopoulos et al., 1994). 
MSI has also been found in sub-sets of sporadic tumors of types that 
characterize the HNPCC syndrome, including cancer in the colon, rectum, 
endometrium, pancreas and stomach (Han et al, 1993; Lothe et al., 1993; 
Peltomaki et al., 1993a & Risinger et al, 1993). The same phenotypic 
instability has been observed in a variety of sporadic malignancies, including 
those of the colon, endometrium, stomach, pancreas, lung, bladder, kindey, and 
esophagus (Gonzalez et al., 1993; Han et al., 1993; lonov et al., 1993; Thibodeau 
et al., 1993; Meltzer et al., 1994; Merio et a�.,1994; Mironov et al., 1994; Rhyu 
et al., 1994; Shridhar et al., 1994 & Uchida et al., 1994). 
MSI may reflect a high mutation rate in genes that are essential for normal 
cell function and growth, thus contribute to tumor initiation and progression, 
analogous to the mechanism of the remaining wide-type allele (Hemminki et al., 
1994). Hence, the concept that MSI is a sensitive indicator of a mutator 
phenotype in cancer is receiving increasing experimental support. 
The mutation phenotype (RER phenotype) of MSI is seen as allelic mobility 
shifts during electrophoretic runs (Aaltonen et al” 1993; lonov et al., 1993; 
• Lindblom et al., 1993; Peltomaki et al., 1993 & Thibodeau et al., 1993). It is 
nonselective. MSI may merely be a sensitive indicator of genomic 
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hypermutation (Loeb, 1994). 
1.2.4 MSI in Various Cancers 
Since the initial description in 1993 of MSI in a class of familial colon 
carcinomas, HNPCC (Aaltonen et al., 1993; lonov et al., 1993 & Thibodeau et al, 
1993), MSI has been identified in a wide variety of human cancers, both familial 
and sporadic. Although by now a small but significant proportion of virtually 
every single tumor type has been shown to demonstrate MSI, the highest 
frequency has been reported in HNPCC cases, including examples of the related 
Muir-Torre syndrome, and in Turcot�syndrome (intestinal polyposis, colon 
carcinoma, and brain carcinoma) (Table 1.2.4a). For sporadic colon carcinomas, 
the frequency of MSI positive cases is within the range of 15-20% overall (Table 
1.2.4b), but for sporadic colon carcinomas in patients age < 35 years, the MSI 
positive frequency increases to 58% (Liu et a/., 1995a). This finding suggests 
that a greater proportion of colon carcinoma patients of younger age may have 
inherited a predisposition mutation than could be documented by review of 
family histories alone. 
Concerning MSI in noncolon cancers, it has been suggested that the 
frequency of MSI might be higher in those tumor types that are reported in the 
extended HNPCC spectrum, the Lynch Cancer Family II Syndrome (Peltomaki et 
a/., 1993). Comparative analysis revealed that this may indeed be the case; 
among sporadic tumors the frequency of MSI is higher in pancreatic, endometrial, 
prostate, and gastric carcinomas, commonly found in Lynch II pedigrees, than in 
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breast, ovarian, and other carcinomas less commonly found in Lynch II kindreds 
(lordanis et aL, 1998). 
V 
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Table 1.2.4a MSI in Familial Cancer Syndromes 
Tumor MSI + References 
HNPCC “ 
(colon) 11/14 (79%) Aaltonen et al., 1993 
68/74 (92%) Liu et al, 1996 
8/13 (62%) Risinger et al., 1996 
(endometrial) 3/4 (75%) Risinger et al., 1996 
Muir-Torre 7/13 (54%) Honchel et al., 1994 
Turcot's 3/9 (33%) Hamilton et al, 1995 
� 
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Table 1.2.4b MSI in Nonfamilial Human Solid Tumors 
Tumor MSI + References 
Brain 
(Glioblastoma) 5/16 (31%) Dams et al., 1995 
(Astrocytoma) 1/16 (6%) Dams et al., 1995 
(Glio/astro) 0/32，1/32 Wooster et al, 1994 
(Brain, unspec) 1/54 (2%) Peltomaki et al., 1993 
(Brain, unspec) 0/15 Amariglio et al., 1995 
Neuroblastoma 4/46 (9%) Martinsson et al., 1995 
2/30 (7%) Bergen a/., 1995 
Head & neck 6/20 (30%) El-Naggar et al., 1996 
Oral 6/91 (7%) Ishwad et al., 1995 
Esophagus 
(Adenoca) 8/36 (22%) Meltzer et al., 1994 
(Squamous cell ca) 1/42 (2%) Meltzer et al., 1994 
(Squamous cell ca) 7/35 (20%), 21/35 Ogasawara et al, 1995 
(Squamous cell ca) 22/34 (65%) Wang et al” 1996 
Gastric 4/22 (18%) Mironov et al., 1994 
20/59 (34%) Lin et al., 1995 
(Stomach) 22/57 (39%) Han et al., 1993 
(Stomach) 20/42 (48%) Shinmura et al, 1995 
(Stomach) 8/24 (33%) Semba et al., 1996 
17/75 (23%) Chong etai, 1994 
4/23 (17%) Tamura et al., 1995 
6/33 (18%) Peltomaki et al., 1993 
5/24 (21%) Nakashima et al., 1995 
11/34 (32%) Serucae/a/., 1995 
21/61 (34%) dos Santos et al�1996 
Colon (non-HNPCC) 16/160 (10%) lonov et al., 1993 
6/46 (13%) Aaltonen et al., 1993 
35/207 (17%) Lothe eial, 1993 
37/189 (20%) Liu etal, 1995a 
(Continued) 
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Table 1.2.4b (Continued) 
Tumor MSI + References 
Colon (non-HNPCC) 24/181 (13%) Liu et al., 1995b 
25/90 (28%) Thibodeau et al., 1993 
2/18(11%) Hane/ al, 1993 
7/26 (27%) Fishel etal, 1993 
11/56 (20%) Bocker et al, 1996 
17/80 (21%) Nakashima et al., 1995 
31/108 (29%) Watatani et al., 1996 
Liver 1/29 (3%) Han et al., 1993 
Pancreas 6/9 (67%) Han et al., 1993 
6/8 (75%) Brentnall et al., 1995 
0/26 Seymour et al., 1994 
Bladder 6/200 (3%) Gonzalez-Zulueta et al., 1993 
12/72(17%) Li etal, 1996 
Prostate 13/66 (20%) Egawa et al, 1995 
7/48 (15%) Suzuki etal.,\99S 
3/19 (16%) Lacombe et al., 1996 
Testis 0/86 Peltomaki et al., 1993 
Endometrium 4/18 (22%) Peltomaki et al” 1993 
10/109 (9%) Caduffe/ al., 1996 
12/59 (20%) Katabuchi et al., 1995 
2/22 (9%) Jovanovic et al” 1996 
7/30 (23%) Burks ei al, 1994 
6/36 (17%) Risinger et al., 1993 
18/77 (23%) Kobayashi et al； 1996 
4/18 (22%) Peltomaki et al., 1993 
9/45 (20%) Duggan et al., 1994 
6/20 (30%) Helland et al., 1997 
23/83 (28%) Toshimasa et al” 1998 
Ovary 0/20, 2/20 Wooster et al” 1994 
1/19(5%), 3/19 Han etai, 1993 
(Continued) 
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Table 1.2.4b (Continued) 
Tumor MSI + References 
Ovary 4/74 (5%) Pieretti et al., 1995 
8/47 (71%) Fujitae/a/.，1995 
10/90 (11%) Arzimanoglou et al, 1996 
7/49 (14%) Tangir et al., 1996 
2/68 (3%) Kobayashi et al., 1995 
2/17 (12%) Shenson et al., 1995 
Uterus 2/13 (15%) Han et al., 1993 
Cervix 
(CIN) 3/14 (21%) Mitra et al., 1995 
7/47 (15%) Jimenez et al., 1998 
5/19* (26%) Fouret et al., 1998 
19/37(51%) Ometal, 1999 
1/37 (3%) Nishimura et al., 2000 
(Cervical carcinoma) 2/13 (15%) Han et al., 1993 
6/46(13%) Mitra et al., 1995 
5/89(6%) Larson et al., 1996 
5/82(6%) Helland et al, 1997 
3/57(5%) Chu etal., 1998 
3/54 (6%) Rodriguez et al., 1998 
6/16* (38%) Fouret et al., 1998 
9/23* (39%) Fouret et al., 1998 
3/80 (4%) Ou etal, 1999 
8/35 (23%) Nishimura et al., 2000 
25/100 (25%) Chung et al., 2001 
Breast 2/78 (3%) Shaw et al., 1996 
1/26 (4%) Han et al, 1993 
1/104 (1%), 11/104 Wooster etal, 1994 
4/20 (20%) Yee etal, 1994 
0/84 Peltomaki et al, 1993 
2D/69 (29%) Karnik etal, 1995 
(Continued) 
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Table 1.2.4b (Continued) 
Tumor MSI + References 
6/28 (22%) Contegiacomo et al., 1995 
11/97 (11%) Paulson et al., 1996 
1/30 (3%), 2/30 Jonsson et al., 1995 
Lung (Small cell) 15/33 (45%) Merlo et al., 1994 
(Small cell) 0/37 Adachi et al” 1995 
(Nonsmall cell) 7/108 (7%) Fong et al., 1995 
(Nonsmall cell) 13/38 (34%) Shridhar et aL, 1994 
(Nonsmall cell) 16/55 (29%) Adachi et al., 1995 
0/85 Peltomaki et al, 1993 
25/51 (49%) Miozzo et al., 1996 
Sarcoma 
(Kaposi's) 2/7 (29%) Bedi et al., 1995 
(Soft tissue) 2/18 (11%) Peltomaki et al., 1993 
(Gynecol) 6/44, 11/44 Risinger et al., 1995 
* This was the total number of the presence of MSI or LOH. 
� 
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1.2.5 The Role of MSI in Carcinogenesis 
Mutations inactivating both alleles of individual DNA mismatch repair 
genes have been reported in phenotypically normal tissue (Parsons et al., 1995), 
and MSI has been demonstrated in nonmalignant tissue. The latter includes 
neurofibroma, which does not become malignant in the vast majority of cases 
(Ottini et al., 1995). MSI also was found in six of ten patients with ulcerative 
colitis whose colonic mucosa was histologically negative for dysplasia (Brentnall 
et al., 1996)，and in eight of nine patients with nonneoplastic pancreatitis 
(Brentnall et al., 1995). These findings suggest that some forms of genomic 
instability may be compatible with a normal phenotype, and may not directly lead 
to carcinogenesis. 
Similar MSI frequencies have been demonstrated in solitary and multiple 
gastric tumors (Nakashima et al, 1995) and in primary and metastatic (to liver) 
colorectal carcinomas (Ishimaru et al., 1995). Both examples suggest that MSI 
can occur early in tumor progression. Furthermore, the presence of genomic 
instability in either aberrant crypt foci isolated form patients with colon 
carcinoma (Augenlight et al., 1996) or in precancerous lesions of the stomach 
(Semba et al., 1996) suggests that genomic instability can be a very early event in 
the tumor development. However, MSI has been demonstrated to be a late event 
in other tumor types, including nonsmall cell lung carcinomas (Adachi et al., 
1995)，sporadic breast tumors (Karnik et al” 1995), and head and neck squamous 
‘ carcinomas (El-Naggar et al” 1996); in the glioma lineage, late stage 
glioblastomas were found to be MSI positive whereas early stage astrocytomas 
— -
Chapter I Introduction 
were MSI negative (Dams et al., 1995). Therefore, there is currently no 
consensus as to when in the course of tumorigenesis MSI develops. 
1.2.6 MSI as a Diagnostic / Prognostic Tool 
The use of MSI can be proven valuable as a diagnostic tool to identify 
HNPCC patients who would have been excluded by clinical criteria alone (Muta 
et al., 1996). MSI also can be used to determine whether a tumor, like breast 
carcinoma, that is uncommonly part of the Lynch II syndrome, is heritable or 
sporadic when it occurs as a member of a Lynch II family (Risinger et al,, 1996). 
Several reports strongly support the value of mismatch DNA repair gene 
mutation screening in kindreds with inconclusive histories. Nystrom-Lahti et al. 
detected a 165-base pair deletion, previously identified in 14 of 30 Finnish 
HNPCC kindreds, in 4 of 22 individuals from families with colorectal carcinoma 
who failed to meet the Amsterdam criteria for HNPCC (Nystrom-Lahti et al., 
1995 & Nystrom-Lahti et al., 1996). Liu et al. found germline hMSH2 
mutations in 5 of 12 colorectal carcinoma patients age < 35 years who again did 
not meet the Amsterdam criteria (Liu et al., 1995a). Another report by Moslein 
et al. noted that germline mismatch DNA repair mutations were found to be 
distributed among 1 sporadic (14%), 3 familial (16%), and 9 HNPCC (45%) 
cases (Moslein et al, 1996). Linkage can be added to MSI testing and direct 
mutation analysis to characterize presymptomatic members of presumptive 
� 
HNPCC families. Recently, a new technique involving examination of hMSH2 
/ hMLHl protein expression by immunohistochemistry was added to the battery 
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of tests that can be applied to identify individuals who may carry germline 
mutations (Thibodeau et al., 1996). In an attempt to gain further insight into the 
biologic significance of MSI, Dunlop et al. reported that relatives of HNPCC 
patients carrying germline mismatch DNA repair mutations share an increased 
risk developing HNPCC or other types of cancer (Dunlop et al., 1997). 
參 
Data supporting the potential of MSI as a prognostic / diagnostic tool in 
non-HNPCC cancers also have been reported. Molecular analysis of 14 families 
with Turcot's syndrome revealed two distinct subsets: three families of 
individuals with glioblastomas and colon adenomatous polyps who were MSI 
positive, with identified DNA mismatch repair gene mutations; and 11 families of 
individuals with medulloblastomas and adenomatous polyps of the colon who 
were MSI negative, with no evidence of DNA mismatch repair gene mutations 
(Hamilton et al., 1995). The association of a distinctive brain tumor type with 
characteristic MSI status and genotype suggests that genomic instability testing 
can distinguish between likely inherited mutation negative and mutation positive 
individuals. 
Tangir et al. reported that borderline ovarian tumors exhibit a significantly 
higher frequency of MSI when compared with invasive epithelial ovarian tumors 
(Tangir et al” 1996). In addition, dos Santos et al. reported that patients with 
gastric tumors with multiple MSI positive loci have a better clinical outcome (dos 
Santos et al., 1996). Lukish et al. reported that patients with MSI positive 
� 
colonic tumors have significantly better prognosis (Lukish et al, 1998). 
However, in breast carcinoma patients a statistically significant correlation 
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between the presence of MSI and poor prognosis has been reported (Paulson et 
al., 1996). These discrepancies suggest the need to expand the studies to a large 
number of tumors of multiple tumor type to determine whether MSI can be used 
as prognostic indicator. 
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CHAPTER II AIMS OF THE STUDY 
Carcinoma of the uterine cervix is a common malignancy among women 
worldwide, and mortality rates from this cancer are high (Wingo et al., 1995). 
Most cervical carcinomas are believed to be preceded by distinct preneoplastic 
epithelial changes designated "dysplasia" or "CIN". The biological behavior of 
dysplasias varies in their progression to invasive cancer (Luthra et al., 1987 & 
Ostor，1993), suggesting a role for specific etiologic agents or genetic alterations 
in the progression of dysplasias to invasive cancer. The genetic basis of this 
progression is poorly understood. 
An important factor of rapid accumulation of genomic changes lies on 
genomic instability (Loeb, 1991) and / or incapability of the cell to repair 
damaged DNA (Fishel et al,, 1993). Microsatellites are invariably inherited 
repeated DNA sequences scattered throughout chromosomes (Hearne et al., 
1992). The characteristic nature of size-polymorphism and error-prone 
replication has made them widely utilized genetic markers for allelotyping and 
genomic stability in various tumors. Alteration of the number of DNA repeats 
in microsatellites (or MSI) is typically found in tumors from HNPCC patients 
genetically defective in DNA mismatch repair (Aaltonen et al” 1993), as well as 
in various sporadic cancers (Honchel et al., 1995). Pervious study showed that 
� 
MSI in colorectal cancer is associated with a good prognosis (Thibodeau et al., 
1993)，but in breast carcinoma patients a statistically significant correlation 
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between the presence of MSI and poor prognosis has been reported (Paulson et 
al., 1996). 
HPV has been recognized as a major etiologic factor for cervical cancer and 
its premalignant lesion, i.e., SIL or CIN (Munoz et al., 1992b). Infection with 
high-risk types of HPV in the basal cells of cervical squamous epithelium affects 
the differentiation program and induces a progressive proliferation and dysplasia 
of the epithelial cells. The progression of low grade CIN is typically infrequent 
and slow. Most studies have suggested that less than 15% of women with low 
grade CIN (CIN-L) will subsequently develop high grade CIN (CIN-H). 
However, once committed to CIN-H changes, most patients will eventually 
develop invasive cancer, given a long (usually more than one decade) duration of 
cancer evolution (Kiviat, 1996). 
In order to understand the role of MSI in the evolution of cervical neoplasms, 
MSI was determined in CIN-L, CIN-H and invasive cervical carcinoma at ten 
loci BAT 25, BAT 26, D2S123, D5S346, D17S250, BAT 40，D3S1263, D4S402, 
D5S406 and D11S912 using radioactive labeling. We also looked for 
correlation between these findings and clinicopathological parameters or HPV 
infection. The present study was then designed with the following aims: 
1 • To choose a better panel of MSI microsatellite markers for detecting the 
. presence of MSI in cervical neoplasm; 
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2. To investigate the role of MSI in cervical carcinogenesis by examined the 
incidence of MSI in normal cervix, CIN and invasive carcinoma; 
3. To explore the association between MSI and a number of clinical and 
pathological parameters in invasive cervical carcinoma; 
4. To investigate the HPV infection in cervical neoplasm and the interaction 
between HPV infection and MSI status in invasive cervical carcinoma. 
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CHAPTER III MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Patients and Specimens 
In this study, 196 patients were included. Of which 20 cases had normal 
cervix, 83 cases were CIN and 93 cases were cervical invasive carcinoma. The 
clinical data of patients were collected until the last date of follow-up. The 
histological type and grade of the neoplasms were classified according to the 
criteria of the World Health Organization (WHO) and the stage of carcinomas 
was established according to the International Federation of Gynecologists and 
Obstetricians (FIGO) criteria. Of 83 CIN cases, 24 cases were diagnosed as low 
grade CIN (CIN-L) (corresponding to CIN grade 1) and 59 cases were diagnosed 
as high grade CIN (CIN-H) (corresponding to CIN grade 2 and 3). In 93 cases 
of invasive carcinoma, there were 14 cases of Grade 1，53 cases of Grade 2 and 
26 cases of Grade 3. Besides, 39 cases of carcinoma were Stage I, 33 cases 
were Stage II，16 cases were Stage III and 5 cases were Stage IV. All of them 
were squamous cell carcinoma. 
All the study subjects were recruited after obtaining informed consents at the 
Department of Obstetrics & Gynaecology，Prince of Wales Hospital. Normal 
cervical specimens were obtained form the patients suffering from benign disease. 
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Cervical neoplastic tissues were obtained by colposcopic biopsy or collected from 
patients undergoing surgical operation. Matched peripheral blood samples were 
collected before surgery. All the tissue specimens and blood samples, when 
available, were snap-frozen in liquid nitrogen and stored at -70°C pending 
analysis. 
3.1.2 Microsatellite Markers 
Ten microsatellite markers were used to detect MSI in this study. The first 
panel of five loci was recommended by "The International Workshop on 
Microsatellite Instability and RER Phenotypes in Cancer Detection and Familiar 
Predisposition" (Boland et al,, 1998). This was a working "reference" panel of 
markers, which had been validated for detection of MSI in colorectal cancer, and 
was encouraged to be evaluated for detection of MSI in other tumours. The first 
panel was composed of five loci, including BAT25, BAT26, D2S123, D5S346 
AND D17S250. In addition, the second panel of five loci was selected based on 
previous studies of MSI in cervical neoplasms (Mitra et al, 1995 & Ip，1999). 
These included BAT40, D3S1263, D4S402, D5S406 and D11S912. Information 
of primer sequences was obtained from the Genome Data Base Home Page on the 
World Wide Web (Johns Hopkins University) (Table 3.1.2a). Primer pairs were 
synthesized by Integrated DNA Technologies, Coralville, I A, USA. 
� 
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Table 3.1.2a Microsatellite Markers used for Detection of MSI 
Name of Locus Location Size of Primer Sequence 
Primer Symbol Product (bp) 
BAT-25.1 BAT 25 4ql2 -90 5'-TCGCCTCCAAGAATGTAAGT-3' 
BAT-25.2 5'-TCTGCATTTTAACTATGGCTC-3' 
BAT-26.1 BAT 26 2pl6 80-100 5'-TGACTACTTTTGACTTCAGCC-3' 
BAT-26.2 5'-AACCATTCAACATTTTTAACCC-3' 
AFM093xh3a D2S123 2pl6 197-227 5'-AAACAGGATGCCTGCCTTTA-3' 
AFM093xh3m 5'-GGACTTTCCACCTATGGGAC-3' 
LNS-CAI D5S346 5q21-q22 96-122 5'-ACTCACTCTAGTGATAAATCGGG-3' 
LNS-CAH 5'-AGCAGATAAGACAGTATTACTAGTT-3' 
MfdlSCA D17S250 17qll.2-ql2 151-169 5'-GGAAGAATCAAATAGACAAT-3' 
Mfd 15GT 5'-GCTGGCCATATATATATTTAAACC-3' 
BAT-40.1 BAT 40 lpl3.1 80-100 5'-ATTAACTTCCTACACCACAAC-3' 
BAT-40.2 5'-GTAGAGCAAGACCACCTTG-3' 
AFM079yg5a D3S1263 3p25-24.2 231-249 5'-CTGTTGACCCATTGATACCC-3' 
AFM079yg5m 5'-TAAAATCACAGCAGGGGTTC-3' 
AFM151xc3a D4S402 4pter-4qter 287-323 5'-CTTACTGTGTTGCCCAAGGT-3' 
AFM 151xc3m 5'-AGCTCTATGATTCATTTCAAGTTTG-3' 
AFM154xg3a D5S406 5pter-5qter 160-186 5'-CCTGCCAATACTTCAAGAAA-3' 
AFM 154xg3m 5'-GGGATGCTAACTGCTGACTA-3' 
AFM157xh6a D11S912 llq25 101-123 5'-TCGTGAGANTACTGCTTTGG-3' 
AFM157xh6m 5'-TTTTGTCTAGCCATGATTGC-3' 
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3.2 Methods 
3.2.1 Preparation of OCT-embedded Specimen Sections 
The tissue specimens were embedded with Optimal Condition Temperature 
(OCT) compound (Miles Inc., Diagnostic Division, Elkhart, IN, USA) and 
snap-frozen in liquid nitrogen. Consecutive sections of lO^m were cut from the 
OCT-embedded tissues by a cryo-microtome (Model no. Cryocut 1800; Leica, 
Germany), All the specimen sections were mounted on non-coated glass 
microscopic slides. A section of 5|im was cut after every fifteen consecutive 
sections of 10|im. These sections were mounted on a separate coated glass 
microscopic slide, which were used as a guide for the microdissection of target 
cells from specimen sections. After sectioning, all the sections were fixed in 
acetone at room temperature for 10 minutes. Then the specimen sections were 
stored at -20°C. 
The guided sections were stained with haemotoxylin and eosin (H&E 
staining). After staining, the guided sections were dehydrated with an 
up-graded alcohol series, 70%, 80%, 95% and 100% alcohol, each for about 5 
minutes. They were cleared twice in xylenes for 2 minutes each time and 
mounted with Histomount (Catalog no. 360294H; BDH, England, UK). The 
guided sections were used to corroborate the histological diagnosis and determine 
the location of target cells in the frozen specimens. The histological type and 
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grade of the neoplasms were classified according to the criteria of the World 
Health Organization. 
3.2.2 Microdissection of Epithelial Cells and Neoplastic Cells 
from Specimen Sections 
The guided sections were used for locating the target cells during 
microdissection. One frozen specimen section was taken out from freezer for 
microdissection each time. Sterile needles and sterile blades were used to pick 
out the target cells under a dissecting microscope (Model no. SMZ-1; Nikon, 
Japan). New sterile needles and sterile blades would be used in microdissection 
of target cells from specimen sections of each case. Neoplastic cells were 
collected from the CIN and cervical carcinoma tissues, while epithelial cells were 
collected from the normal cervix. Microdissected cells were then transferred to 
a clean 1.5 ml microfuge tube containing 20 TE buffer (10 mM Tris-HCl, pH 
8.0 and ImM EDTA) and stored at 4°C. 
3.2.3 DNA Extraction 
Genomic DNA was extracted from blood samples and frozen normal / tumor 
specimens. DNA extraction from blood cells was prepared by the methods of 
proteinase K digestion and phenol / chloroform extraction according to Sambrook 
et al. (Sambrook et al.., 1989)，while DNA from frozen dissected cells was 
extracted using PURIGENE® DNA Isolation Kits (Centra Systems, USA). 
^ — 
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Then the integrity of DNA was identified using -actin gene PCR (Wong et al., 
1997). 
3.2.3.1 Normal Blood 
Proteinase K Digestion 
Blood cells were transferred to a clean 5 ml tube. Lysis Buffer was added 
up to 5 ml to the tube. Then the sample was shaken well at room temperature 
for 5 minutes and centrifuged at 15,000 rmp at 4°C for 20 minutes. The 
supernatant was poured off and the pellet inside the tube was resuspended using 2 
- 3 ml TE buffer. After that, 100 - 150 |il 10% Sodium Dodecyle Sulfate (SDS; 
Gibco BRL, California, USA) and 20 - 30 i^l Proteinase K (20 mg/ml; Gibco 
BRL, California, USA) were added. The sample was incubated overnight at 
55°C for digestion. 
Phenol / Chloroform Extraction 
When the digestion was completed, 2 - 3 ml Phenol (Ultra Pure, Gibco BRL, 
California, USA) was added to the tube. The sample was shaken well and 
centrifuged at 3,000 rmp at 4°C for 10 minutes. Then the clear supernatant was 
poured into a clean 5 ml tube containing 2 - 3 ml phenol / chloroform. The 
phenol / chloroform mixture was shaken well again and centrifuged at 3,000 rmp 
at 4°C for 10 minutes. Then the clear supernatant was poured into a clean 5-ml 
- -
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tube containing 2 - 3 ml chloroform. As before, the chloroform mixture was 
shaken well and centrifuged at 3,000 rmp at 4°C for 10 minutes. Then the clear 
supernatant was poured into a clean 15 ml tube containing 20 - 30 jil NaOAC 
(3M) / Na40AC / Ammonium acetate and 4-6 ml cold absolute alcohol. When 
the sample was shaken gently, DNA would be visible as a small white pellet, 
which was then centrifuged down at 13,000 rmp at 4°C for 2 minutes. 
After precipitation, DNA pellet with absolute alcohol was transferred to a 
clean 1.5 ml microfuge tube and centrifuged at 13,000 rmp for 2 minutes. Then 
the supernatant was poured off and 1 ml 70% ethanol was added to wash the 
DNA pellet. Then the 70% ethanol was poured off and the tube containing 
DNA pellet was vacuum dried. After drying, the DNA pellet was resuspended 
using 25 |il TE buffer. Then the DNA would be stored at -20�C. 
3.2.3.2 Dissected Cells 
Cell Lysis 
50 \i\ Cell Lysis Solution was added to the 1.5 ml microfuge tube containing 
target cells. It was pipetted up and down to lyse the cells. Then the cell 
clumps were dissolved by heating at 65°C for 5 minutes. If the cells clumps 
were still visible, 0.25 Proteinase K Solution (20 mg/ml) was added to the cell 
lysate to achieve maximum yield. The solutions were mixed by inverting 25 
times and incubated at 55°C for 1 hour to overnight or until cell clumps were 
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dissolved. 
RNase Treatment 
After the cell clumps were dissolved, 0.25 \x\ RNase A Solution (4 mg/ml) 
was added to the cell lysate. The sample was mixed by inverting the tube 25 
times and incubated at 37°C for 1 hour. 
Protein Precipitation 
After incubation, the sample was cooled to room temperature. 16.7 |il 
Protein Precipitation Solution was added to the RNase A-treated cell lysate. 
Then the mixture was vortexed vigorously at high speed for 20 seconds and 
incubated in ice for 5 minutes. It was centrifuged at 13,000 rmp for 3 minutes. 
The precipitated proteins would form a tight pellet. 
DNA Precipitation 
The supernatant containing the DNA (leaving behind the precipitated protein 
pellet) was poured into a clean 1.5 ml microfuge tube containing 50 |il 100% 
Isopropanol (2-propanol). 0.083 |il Glycogen Solution, a DNA carrier, 
(20mg/ml; catalog no. R-5010; Gentra Systems, USA) was added per 50 |il 
Isopropanol. The sample was mixed by inverting 50 times gently. Then it was 
centrifuged at 13,000 rmp for 5 minutes. The DNA would be visible as a small 
white pellet. The supernatant was poured off and the tube was drained on a 
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clean absorbent paper. 
50 |il 70% Ethanol was added and the tube was inverted several times to 
wash the DNA pellet. It was centrifliged at 13,000 rmp for 5 minutes. Then 
the ethanol was poured off carefully. The tube was inverted and drained on a 
clean absorbent paper and allowed to air dry for 10-15 minutes. 
DNA Hydration 
When the tube was dried, 25 nl DNA Hydration Solution was added. It 
was incubated overnight at room temperature to rehydrate the DNA. Then the 
DNA would be stored at -20°C. 
3.2.4 DNA Amplification 
Microsatellite mononucleotide regions on chromosome 2，3，4，5，11 and 17, 
and dinucleotide regions on 1, 2 and 4 were amplified by polymerase chain 
reaction (PGR) using end-labeling of oligonucleotide primers. 
3.2.4.1 End-labeling of Primers 
Prior to the polymerase chain reaction, each sense primer was end-labeled 
with [ r 32p]ATP (Amersham Pharmacia Biotech, UK Limited, England) at the 
� 
5'-end using T4 polynucleotide kinase (New England Biolabs, USA) per reaction. 
The reaction was performed in l-^il volume containing 14 mM Tris-HCl (pH 7.6)， 
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20 mM KCl, 2 mM MgCb, 0.2 mM 2-mercaptoethanol, 1 uCi [ r ^^P]ATP, 0.6 
I^ M of sense primer and 240 unit of T4 polynucleotide kinase. 
The mixture was incubated at 37°C for 30 minutes and completed at 65°C 
for 10 minutes. This was performed in the Programmable Thermal Controller, 
PTC-IOOTM (Model no. MJ; Massachusetts, USA). 
3.2.4.2 Polymerase Chain Reaction 
Polymerase Chain Reaction (PGR) was performed in 10-|il volumes 
containing 25 ng of DNA, 7 mM Tris-HCl (pH 8.3)，20 mM KCl, 1.5 mM MgCh, 
200 i^ M deoxynucleotide triphosphates, 0.6 |im of each primer, and 0.5 unit of 
Tag polymerase (Gibco BRL, California, USA). Samples without DNA were 
included for each primer set as negative controls. 
For the first panel of five loci, PCR was performed with an initial 10-minute 
denaturation step at 95°C. Then the thirty cycles were at 94°C for 30 seconds, 
55°C for 30 seconds and 72°C for 45 seconds. This was followed by a 7-minute 
completion step at 72°C. 
For the second panel of five loci, PCR was performed with an initial 
3-minute denaturation step at 94°C, then, coupled to so called 'touch down' cycles 
to solve background problems. The first ten cycles were at 94°C for 30 seconds, 
59°C for 30 seconds and 72°C for 45 seconds. The eleventh to thirtieth cycles 
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were at 94°C for 30 seconds, 55°C for 30 seconds and ITC for 45 seconds. 
This was followed by a 7-minute completion step at 72°C. 
All the reactions were performed in the Programmable Cycler (Model no. 
9700; Perkin-Elmer, USA). 
3.2.5 Denaturing Polyacrylamide Gel Electrophoresis 
After the reactions, the PGR products underwent electrophoresis on 32% 
formamide - 8% polyacrylamide gels with TBE electrophoresis buffer (containing 
10.8 g/L Tris Base, 5.5 g/L Boric Acid, and 4 ml/L Ethylenediaminetetraacetic 
Acid - 0.5 mol/L, pH 8.0，EDTA; Sigma, St. Louis, USA) using Sequencing Gel 
Electrophoresis Apparatus, Model S2 (Gibco BRL, California, USA). 
Polyacrylamide gel was prepared in 60-ml volumes containing 14 ml 40% 
acrylamide solution (Aery 1 amide : Bis-acrylamide = 19 ： 1)，19.2 ml deionized 
formamide (BDH, England, UK), 20.16 g Urea (Enzyme Grade; Gibco BRL, 
California, USA), 6 ml TBE buffer (lOX), 36 TEMED 
(N,N,N',N'-Tetramethlethulenediamine; Pharmacia Biotech, Washington, USA), 
and 0.066 g ammomium persulfate (APS; Sigma, St. Louis, USA). 0.4-mm 
thick gel was set, which would polymerize after 1 hour at room temperature. 
Before loading, the PGR products were denatured at 95°C for 10 minutes and 
kept at 4°C, while the gel was warmed up by undergoing pre electrophoretic run 
for 1 hour. Then 3 fil PCR products from each sample were loaded per well. 
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Electrophoretic run was undergone at 50 W at room temperature. 
3.2.6 Autoradiography 
The electrophoretic gel was peeled off from the glass plate and placed on a 
paper (Whatman 3mm). Then it was vacuum dried at 75°C for 30 minutes by 
the Slab Gel Dryer, SE 1160 Drygel, SR (Hoefer, San Francisco, USA), and 
exposed to X-ray film. 
3.2.7 Determination of MSI 
MSI was scored as positive when a shift and or gain of electrophoretic bands 
were seen in any one of ten loci tested by comparing paired tumor and blood 
DNA. Then it was confirmed by a second PCR and electrophoretic run. 
After detection of MSI using ten microsatellite markers, the case showing 
instability in three or more markers was identified as the high frequency MSI 
(MSI-H) case, while the case showing instability in two or less markers was 
identified as the low frequency MSI (MSI-L) case. However, the case showing 
no apparent instability in any of the 10 markers was identified as the 
microsatellite stability (MSS) case. 
— -
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3.2.8 HPV Detection 
The sample DNA was amplified using a pair of degenerate consensus 
primers MYll and MY09. The region ( �4 5 0 bp in length) in the highly 
conserved LI open reading frame (ORF) of HPV was targeted. Each of the (3 
globin primers GH20 and PC04, yielding a human globin product of 268 bp, 
was worked as an internal control (Resnick et al., 1990). CaSki and HeLa cell 
lines purchased from the American Type Culture Collection, USA was used as 
positive controls for HPV-16 and HPV-18 analyses, respectively. Then the PCR 
products amplified with primers MYll / MY09 were sequenced and subjected to 
2% agarose gel electrophoresis. The PCR products within the expected sizes of 
HPV-16 and HPV-18 were visualized with an ultraviolet light source and 
analyzed using imaging system GelDoc 1000 (Bio-Rad Laboratories, USA). 
If the DNA samples could not be identified in the detection of HPV-16 and 
HPV-18, the residual PCR products of that samples would then be undergone the 
Restriction Fragment Length Polymorphism (RFLP). The PCR products were 
digested with restriction enzyme Rsa I and Dde I (SuRE / Cut Buffer Set, 
Boehringer-Mannheim). Then the products of the reaction were undergone 
electrophoresis in 2% agarose gel staining with ethidium bromide, which were 
visualized with an ultraviolet light source and analyzed using imaging system 
GelDoc 1000 (Bio-Rad Laboratories, USA). The expected bands after the 
restriction enzyme digestion were analyzed by comparing their sizes with the 
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DNA standard size marker. 
3.2.9 Statistical Analysis 
Statistical analysis of correlation between observed MSI and HPV infection, 
and between observed MSI and clinicopathological characteristics were 
performed using Pearson's Chi-square test and Fisher's Exact test. The survival 
data were performed using the Kaplan-Meier technique and compared using the 
log-rank test. All the statistics were analyzed with 95% Confident Interval. 
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CHAPTER IV RESULTS 
4.1 Incidence of MSI in Cervix 
In this study, PGR amplifications of ten mononucleotide and dinucleotide 
microsatellite markers were successfully done in all DNA samples from 20 
normal cervixes, 83 CIN and 93 invasive carcinomas with respective matched 
peripheral blood DNA. MSI was scored as positive when a shift and or gain of 
electrophoretic bands were seen in any one of ten loci tested by comparing paired 
tumour with blood DNA. 
4.1.1 Incidence of MSI in Normal Cervix 
A total of 20 normal cervixes were analyzed for MSI as a negative control. 
None of the microsatellite loci showed MSI. All of the cases were classified as 
microsatellite stability (MSS). 
4.1.2 Incidence of MSI in CIN 
83 cases of CrN were analyzed for MSI. Of which 24 cases were 
diagnosed as low grade CIN (CIN-L) (corresponding to CIN grade 1) and 59 
cases were diagnosed as high grade CIN (CIN-H) (corresponding to CIN grade 2 
and 3). For the cases of CIN-L, none of the microsatellite loci showed MSI. 
All of these were also classified as microsatellite stability (MSS) which was the 
— 
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same as the cases of normal cervixes. On the other hand, MSI was observed in 
1 of 59 (1.7%) cases of CIN-H. This high grade CIN (CIN-490H) was only 
altered at one of the loci (D11S912), so it was classified as the low frequency 
MSI (MSI-L) case (Fig. 4.1.2). 
4.1.3 Incidence of MSI in Cervical Carcinoma 
All 93 cases of invasive carcinoma were histologically diagnosed as 
squamous cell carcinomas. MSI was present in at least one of the ten loci 
examined in 27 of 93 (29.0%) cases (Table 4.1.3a). In 16 of 93 (17.2%) cases, 
MSI was present in two or less loci, so these were classified as the low frequency 
MSI (MSI-L) cases. In 11 of 93 (11.8%) cases，MSI was present in three or 
more loci, so these were classified as the high frequency MSI (MSI-H) cases 
(Table 4.1.3b). 
For the 1st panel of microsatellite markers (Fig. 4.1.3a)，MSI were observed 
in 9 (9.7%) cases at BAT 25, 1 (1.1%) case at BAT 26，8 (8.6%) cases at D2S123, 
9 (9.7%) cases at D5S346 and 11 (11.8%) cases at D17S250 (Table 4.1.3c). For 
the 2nd panel of microsatellite markers (Fig. 4.1.3b), MSI was observed in 8 
(8.6%) cases at BAT 40, 7 (7.5%) cases at D3S1263, 6 (6.5%) cases at D4S402, 6 
(6.5%) cases at D5S406 and 9 (9.7%) cases at D11S912 (Table 4.1.3c). 
V 
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Table 4.1.3a MSI-positive in Cervical Carcinoma 
1st Panel of Microsatellite Markers 2nd Panel of Microsatellite Markers 
Code BAT 25 BAT 26 D2S123 D5S346 D17S250 BAT 40 D3S1263 D4S402 D5S406 D11S912 
C-254 - - - + - - - - _ • 
C-302 - - - + - - _ 
C-322 - - - + - - - - - _ 
C-334 - - - - + - - _ _ _ 
C-343 - - + + + - + - - _ 
C-345 - - - - - - + - _ _ 
C-346 - - - + - + - _ + 
C-349 - - - - - - + 
C-350 + - + + + + + + + + 
C-358 - + - _ _ 
C-370 + - + - + - - - + -
C-371 + - - - + - - - + _ 
C-376 + - + + + + - + + + 
C-384 + - + + + + - - + 
C-403 - - - - + - - _ _ _ 
C-404 + - - - - - - - _ _ 
C-407 + - + + - + + + + 
C-4Q8 - - - + - - -
C-409 - - - - - + - + _ + 
C-422 - - + + + + _ + 
C-425 - - - - - - - + . _ 
C-438 - - - + _ • _ 
C-474 - - + - + + + _ _ + 
C-488 + - - - - - _ 
C-489 + - - - - -
C-512 + - + + 
C-525 I _ I _ I - I - I - + -
(+) MSI-positive; (-) MSI-negative 
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Table 4.1.3b Incidence of MSI in Cervical Carcinoma (n = 93) 
Number of Cervical Carcinoma (%) 
MSI-positive 
MSI-L (2 or less loci) 16 (17.2) 
MSI-H (3 or more loci) 11 (11.8) 
MSI-negative 
MSS 66(71.0) 
MSI-L = Low frequency MSI 
MSI-H = High frequency MSI 
MSS = Microsatellite Stability 
Table 4.1.3c Incidence of MSI in Cervical Carcinoma in different loci (n = 93) 
Number of MSI-positive in 
Cervical Carcinoma (%) 
1st Panel of Microsatellite Markers 
BAT 25 9 (9.7) 
BAT 26 1(1.1) 
D2S123 8 (8.6) 
D5S346 9(9.7) 
D17S250 11 (11.8) 
2nd Panel of Microsatellite Markers 
BAT 40 8 (8.6) 
D3S1263 7 (7.5) 




Figure 4.1.2 MSI at the locus D11S912 in CIN-H. 
B, normal blood DNA; T, tumor DNA; arrows indicate the 




Figure 4.1.3a MSI at the 1st panel microsatellite markers in cervical 
carcinoma. 
B, normal blood DNA; T, tumor DNA; arrows indicate the 
shifted or novel electrophoretic bands in tumor DNA. 
i) MSI at the locus BAT 25 in cervical carcinoma. 
ii) MSI at the locus BAT 26 in cervical carcinoma. 
iii) MSI at the locus D2S123 in cervical carcinoma. 
iv) MSI at the locus D5S346 in cervical carcinoma. 
V) MSI at the locus D17S250 in cervical carcinoma. 
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Figure 4.1.3b MSI at the 2nd panel microsatellite markers in cervical 
carcinoma. 
B, normal blood DNA; T, tumor DNA; arrows indicate the 
shifted or novel electrophoretic bands in tumor DNA. 
i) MSI at the locus BAT 40 in cervical carcinoma. 
ii) MSI at the locus D3 S1263 in cervical carcinoma. 
iii) MSI at the locus D4S402 in cervical carcinoma. 
iv) MSI at the locus D5S406 in cervical carcinoma. 
V) MSI at the locus D11S912 in cervical carcinoma. 
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4.1.4 Correlation of MSI-positive with the Evolution of 
Cervical Neoplasm 
MSI were observed (in at least one locus) in 0 of 24 (0.0%) case in CIN-L, 1 
of 59 (1.7%) case in CIN-H and 27 of 93 (29.0%) cases in cervical carcinoma. 
The more severe the cervical neoplasm developed, the higher the incident rate of 
MSI was detected. The difference was statistically significant (p = 0.0000). In 
addition, the incident rate of MSI in cervical carcinoma was statistically higher 
than that in CIN-H (p = 0.0006). 
4.2 Correlation of MSI-positive with Clinicopathological 
Characteristics in Cervical Carcinoma 
In this study, all 93 cases of invasive carcinoma were diagnosed as 
squamous cell carcinomas. The age of 10 patients were below 40 years, 39 
patients were in between 40 to 60 years old and 44 patients were above 60 years 
old. According to the criteria of FIGO (Creaseman, 1989), the clinical stage of 
carcinomas was diagnosed including 39 cases of Stage I, 33 cases of Stage II，16 
cases of Stage III and 5 cases of Stage IV. Besides, using the criteria of WHO 
for tumour grading (WHO, 1975), the distribution of histological grade was 14 
cases of Grade 1，53 cases of Grade 2 and 26 cases of Grade 3. In the clinical 
status, 58 patients were alive without evidence of disease, 9 patients were alive 
• with disease and 26 patients had died. The relationship between the status of 
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MSI and clinicopathological parameters was examined and the results were 
summarized in Table 4.2. 
V 
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Table 4.2 Correlation of MSI-positive with Clinicopathological Characteristics in 
Cervical Carcinoma (n = 93) 
All Number of MSI-positive (%) 
Patients At least 1 locus At least 2 loci At least 3 loci 
Age 
<40 10 2 (20.0) 1 (10.0) 1 (10.0) 
40 - 60 39 13 (33.3) 5 (12.8) 5 (12.8) 
>60 44 12(27.3) 6(13.6) 5 (11.4) 
Stage 
I 39 9(23.1) 2 (5.1) 2(5.1) 
II 33 10 (30.3) 5 (15.2) 4 (12.1) 
i n 16 7 (43.8) 5 (31.3) 5 (31.3) 
IV 5 1 (20.0) 0 (0.0) 0 (0.0) 
Grade 
G1 14 2(14.3) 1(7.1) 0(0.0) 
G2 53 16 (30.2) 8 (15.1) 8 (15.1) 
G3 26 9 (34.6) 3 (11.5) 3 (11.5) 
Status 
NED 58 14(24.1) 5 (8.6) 5 (8.6) 
AWD 9 1(11.1) 1 (11.1) 1(11.1) 
DOD 26 12(46.2) 6(23.1) 5 (19.2) 
ALIVE 67 15 (22.4) 6 (9.0) 6 (9.0) 
DOD 26 12(46.2) 6(23.1) 5 (19.2) 
NED = Alive with no evidence of disease 
AWD = Alive with disease 
DOD = Died of disease 
ALIVE = Alive with disease / no evidence of disease 
* 
Statistically significant difference between "ALIVE" and "DOD" patients (p = 
0.0443). 
� 
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4.2.1 MSI and Age 
All patients were aged from 25 to 84 with a mean age of 58.3 years. They 
were classified into three groups. MSI was observed in at least one locus in 2 of 
10 (20.0%) cases at the age group below 40 years, 13 of 39 (33.3%) cases at the 
age group between 40 to 60 years and 12 of 44 (27.3%) cases at the age group 
above 60 years (Table 4.2). There was no statistically significant difference in 
the incidence of MSI among three age groups (p > 0.05). 
4.2.2 MSI and Clinical Stage 
Based on the FIGO staging criteria (Creaseman, 1989)，cervical carcinomas 
were divided into four clinical stages. In Stage I, there were 9 of 39 (23.1%) 
cases showing MSI in at least one locus. 10 of 33 (30.3%) MSI-positive cases 
were found in Stage II，7 of 16 (43.8%) cases were found in Stage III and only 1 
of 5 (20.0%) cases was found in Stage IV. From Stage I to Stage III, the 
incidence rate of MSI-positive was increasing. However, it decreased in Stage 
IV that might be due to the small sample size (Table 4.2). There was no 
statistically significant difference in the incidence of MSI among four clinical 
stages (p > 0.05). 
4.2.3 MSI .and Histological Grade 
According to the WHO criteria for tumour grading (WHO, 1975), three 
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histological grades of cervical carcinoma were classified. Within 14 cases of 
Grade 1, MSI-positive in at least one locus was observed in 2 (14.3%) cases. 
Besides, in Grade 2 and Grade 3, MSI-positive in at least one locus were found in 
16 of 53 (30.2%) cases and 9 of 26 (34.6%) cases respectively. Thus, the higher 
the histological grade of cervical carcinoma examined, the higher the incidence 
rate of MSI-positive was observed (Table 4.2). However, no statistically 
significant difference in the incidence of MSI among three histological grades 
was found (p > 0.05). 
4.2.4 MSI and Clinical Status 
The period of follow-up from the date of diagnosis among 93 patients was 
ranged from 1 to 92 months with a mean of 41.8 months. There were three 
groups of clinical status in cervical carcinoma patients, i.e. alive with no evidence 
of disease (NED), alive with disease (AWD) and died of disease (DOD). Alive 
with disease / no evidence of disease would be categorized as (ALIVE). 
MSI-positive in at least one locus was observed in 14 of 58 (24.1%) patients who 
were alive without evidence of disease, 1 of 9 (11.1%) patients who was alive 
with disease and 12 of 26 (46.2%) patients who had died of disease. Within 67 
patients who were alive with or without disease, MSI-positive in at least one 
locus was observed in 15 (22.4%) cases, but it was observed in 12 of 26 (46.2%) 
patients who had died of disease (Table 4.2). The difference was statistically 
significant (p = 0.0443). 
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In addition, survival comparisons demonstrated by the Kaplan-Meier 
survival curves were performed using the log rank test. The correlation between 
the MSI status with disease-free survival and overall survival were examined (Fig. 
4.2.4). The 3-year disease-free survival rate for patients with MSI-positive 
tumors and MSI-negative tumors were 55.1% and 67.7% respectively, while the 
5-year disease-free survival rate for patients with MSI-positive tumors and 
MSI-negative tumors were 49.6% and 65.0% respectively. There was no 
significant correlation between the MSI status and the patients who were 
disease-free survival (p > 0.05). 
In the overall survival curve, the patients with MSI-positive tumors showed 
significantly reduced survival rate compared to the patients with MSI-negative 
tumors (p = 0.0201). The 3-year overall survival rate for patients with 
MSI-positive tumors and MSI-negative tumors were 57.6% and 78.6% 
respectively, while the 5-year overall survival rate for patients with MSI-positive 
tumors and MSI-negative tumors were 51.9% and 73.6% respectively. The 
patients with MSI-positive tumors also showed significantly reduced survival rate 
compared to the patients with MSI-negative tumors in both 3-year (p = 0.0169) 
and 5-year (p = 0.0201) overall survival. Thus, patients with MSI-positive 
tumors were found to have a significant poor prognosis. 
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Figure 4.2.4 Kaplan-Meier survival curves for the study population based on 
MSI status, which was defined as MSI-positive when MSI was 
present in at least one locus of the ten microsatellite markers. 
i) Disease-free survival curve for MSI-positive and 
MSI-negative patients. Disease-free survival for 
patients with MSI-positive was 49.6% compared with 
52.0% for those with MSI-negative (log rank test, p > 
0.05). 
Three-year disease-free survival for patients with 
MSI-positive was 55.1% compared with 67.7% for 
those with MSI-negative (log rank test, p > 0.05). 
Five-year disease-free survival for patients with 
MSI-positive was 49.6% compared with 65.0% for 
those with MSI-negative (log rank test, p > 0.05). 
ii) Overall survival curve for MSI-positive and 
MSI-negative patients. Overall survival for patients 
with MSI-positive was 51.9% compared with 73.6% for 
those with MSI-negative (log rank test, p = 0.0201). 
Three-year overall survival for patients with 
MSI-positive was 57.6% compared with 78.6% for 
those with MSI-negative (log rank test, p = 0.0169). 
Five-year overall survival for patients with MSI-positive 
was 51.9% compared with 73.6% for those with 
MSI-negative (log rank test, p = 0.0201). • 
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4.3 Comparison between Two Panels of Microsatellite Markers 
used in MSI Detection 
In this study, ten microsatellite markers were used in MSI detection. The 
first panel was composed of five loci, including BAT 25, BAT 26, D2S123, 
D5S346 and D17S250. The second panel of five loci was composed of the 
other five loci, including BAT 40, D3S1263, D4S402, D5S406 and D11S912. 
In both panels of microsatellite markers, the incident rates of MSI in at least 
one locus were the same, i.e. 19 of 93 (20.4%) cases. This was lower than the 
incident rate of MSI (29.0%) at the total of ten microsatellite markers, but no 
statistically significant difference was found (p > 0.05). 
The correlation of MSI-positive in both panels of microsatellite markers 
with clinicopathological characteristics in cervical carcinoma was summarized in 
Table 4.3. At the age group above 60 years old, the incidence of MSI in the 2nd 
panel was 10 (22.7%) cases, which was higher than that in the 1st panel, i.e. 7 
(15.90/0) cases. Besides, the incident rates of MSI in both panels were similar in 
the clinical stage and histological grade. There was no statistically significant 
difference between the presence of MSI and age at diagnosis, clinical stage or 
histological grade (p > 0.05). 
� 
In the clinical status, the incidence of MSI of patients who had died was 
higher in the 2nd panel, i.e. 10 (38.5%) cases, than that in the 1st panel, i.e. 7 
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(26.9%) cases. In the 2nd panel of microsatellite markers，書 statistically 
significant correlation was found between the presence of MSI and the clinical 
status. 
With analysis in disease-free survival curve and overall survival curve (Fig. 
4.3a)，there was no significant correlation between the MSI status examined using 
the 1 St panel of microsatellite markers and the survival status (p > 0.05). On the 
other hand, the patients with MSI-positive tumors examined using the 2nd panel 
of microsatellite markers showed significantly reduced survival rate compared to 
the patients with MSI-negative tumors in both disease-free survival curve (p = 
0.0200) and overall survival curve (p = 0.0035) (Fig. 4.3b). 
� 
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Table 4.3 Correlation of MSI-positive in the 1st and the 2nd Panel of 
Microsatellite Markers with Clinicopathological Characteristics in Cervical 
Carcinoma 
Number of MSI-positive in at least one locus (%) 
Ml 1st Panel of 2nd Panel of 
yatient^ Microsatellite Markers Microsatellite Markers 
(n = 93) (n=19) (n=19) 
Age 
<40 10 2 (20.0) 1 (10 0) 
40 - 60 39 10(25.6) 8 (20.5) 
>60 44 7(15.9) 10(22.7) 
p = 0.5472 p = 0.6662 
Stage 
I 39 6 (15.4) 5 (12.8) 
n 33 7 (21.2) 8 (24.2) 
HI 16 5 (31.3) 6 (37.5) 
IV 5 1 (20.0) 0(0.0) 
p = 0.6202 p = 0.1199 
Grade 
G1 14 2(14.3) 1(7.1) 
G2 53 11 (20.8) 12(22.6) 
G3 26 6 (23.1) 6 (23.1) 
p = 0M2S p = 0.4082 
Status 
NED 58 11(19.0) 8(13.8) 
AWD 9 1(11.1) 1(11.1) • 
DOD 26 7 (26.9) 10(38.5) 
p = 0,5402 p = 0.0266 
ALIVE 67 12(17.9) 9 (13.4) * * 
DOD 26 7(26.9) 10 (38.5) 
p = 0.4959 p = 0.0164 
NED = Alive with no evidence of disease; AWD = Alive with disease; DOD = 
Died of Disease; ALIVE = Alive with disease / no evidence of d i s e a s e .， 
* 
Statistically significant difference between "NED", "AWD" and "DOD" in 
MSI-positive patients (p = 0:0266). 
* * 
‘ Statistically significant difference between "ALIVE" and "DOD" in 
MSI-positive patients (p = 0.0164). 
Figure 4.3a Kaplan-Meier survival curves for the study population based on 
MSI status, which was defined as MSI-positive when MSI was 
present in at least one locus of the five microsatellite markers in 
the 1 St panel. 
i) Disease-free survival curve for MSI-positive and 
MSI-negative patients. Disease-free survival for 
patients with MSI-positive was 57.9% compared with 
48.6% for those with MSI-negative (log rank test, p > 
0.05). 
Three-year disease-free survival for patients with 
MSI-positive was 57.9% compared with 65.6% for 
those with MSI-negative (log rank test, p > 0.05). 
Five-year disease-free survival for patients with 
MSI-positive was 57.9% compared with 60.7% for 
those with MSI-negative (log rank test, p > 0.05). 
ii) Overall survival curve for MSI-positive and 
MSI-negative patients. Overall survival for patients 
with MSI-positive was 62.0% compared with 68.0% for 
those with MSI-negative (log rank test, p > 0.05). 
Three-year overall survival for patients with 
MSI-positive was 62.0% compared with 75.0% for 
those with MSI-negative (log rank test, p > 0.05). 
Five-year overall survival for patients with MSI-positive 
was 62.0% compared with 68.0% for those with 
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Figure 4.3b Kaplan-Meier survival curves for the study population based on 
MSI status, which was defined as MSI-positive when MSI was 
present in at least one locus of the five microsatellite markers in 
the 2nd panel. 
i) Disease-free survival curve for MSI-positive and 
MSI-negative patients. Disease-free survival for 
patients with MSI-positive was 38.6% compared with 
53.1% for those with MSI-negative (log rank test, p = 
0.0200). 
Three-year disease-free survival for patients with 
MSI-positive was 46.3% compared with 68.7% for 
those with MSI-negative (log rank test, p = 0.0354). 
Five-year disease-free survival for patients with 
MSI-positive was 38.6% compared with 66.4% for 
those with MSI-negative (log rank test, p = 0.0200). 
ii) Overall survival curve for MSI-positive and 
MSI-negative patients. Overall survival for patients 
with MSI-positive was 40.9% compared with 74.1% for 
those with MSI-negative (log rank test, p = 0.0035). 
Three-year overall survival for patients with 
MSI-positive was 49.1% compared with 78.4% for 
those with MSI-negative (log rank test, p = 0.0050). 
Five-year overall survival for patients with MSI-positive 
was 40.9% compared with 74.1% for those with 
MSI-negative (log rank test, p = 0.0035). 
(i) 
1.0 • 
. 9 _ . �  
1 
.8 • —— - "L， 
I �h 
7 I * 
Q — "J*?" - '<"<'\ 
6 . ： o •“ 
e x I 
o � ， . 
£ . 5 . ^ 
13 ^ H 
匕 . 4 • -H—斗 
3 C/5 
.3 I 
.2 I M S I  
M S I +  
.1 . 
0.0 • 
0 10 20 30 40 50 60 70 80 90 100 
Disease-free Survival (Months) 
(11) 
1.0 I^-IL, 
• •：• t , 
.9 i — H ,; 
1-H 
.8 • Mt, 
I •;•：•!• - V "ii 
.7 • 
C  o 
r 6 . 1 o 
& o 
^ -5 • 
• ^ A , ^ 
匕 .4 • •"：？-{• 
OO 
.3 . 
.2 • M S I - 
M S I +  
.1 I  
N 
0 . 0 • 画  
• 0 10 20 30 40 50 60 70 80 90 100 
Overall Survival (Months) 
Chapter IV Results 
4.4 Human Papilloma Virus (HPV) Infection in Cervical Neoplasm 
4.4.1 HPV Infection and Typing in CIN and Cervical 
Carcinoma 
HPV infection was detected in 83 cases of CIN (Table 4.4.1a) and 93 cases 
of cervical carcinoma (Table 4.4.1b). In 83 cases of CIN, HPV DNA was found 
in 72 (86.7%), including 15 of 24 (62.5%) cases in CIN-L and 57 of 59 (96.6%) 
cases in CIN-H. Besides, 79 of 93 (84.9%) cases of HPV infection were found 
in cervical carcinoma (Table 4.4.1c). The incidence of HPV infection in CIN-L, 
CIN-H and cervical carcinoma was 62.5%, 96.6% and 84.9% respectively. The 
difference was statistically significant (p = 0.0003). In addition, the incidence 
of HPV infection in CIN-H was higher than that in CIN-L (p = 0.0001). 
Six types of HPV DNA were detected in CIN-L and CIN-H. These 
included HPV-16, HPV-18, HPV-31, HPV-33, HPV-52 and HPV-58. The 
infection of HPV-16 was found in 4 of 24 (16.7%) cases in CIN-L and 24 of 59 
(40.7%) cases in CIN-H. On the other hand，nine types of HPV DNA were 
detected in cervical carcinoma. These included HPV-11, HPV-16, HPV-18, 
HPV-31, HPV-33, HPV-52, HPV-58, HPV-67 and HPV-70. The infection of 
HPV-16 was found in 52 of 93 (55.9%) cases in cervical carcinoma (Table 4.4.1c). 
The incidence ofHPV-16 infection in CIN-L, CIN-H and cervical carcinoma was 
statistically significant difference (p = 0.0016). Thus, the higher incident rate of 
89 “ 
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HPV-16 infection was observed in the more severe type of cervical neoplasm. 
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Table 4.4.1a HPV Typing in CIN (n = 83) 
Patient Code HPV type Patient Code HPV type Patient Code HPV type 
CIN-367H - CIN-436H 16 CIN-482r~ 33 
CIN-369L - CIN-439H 16 CIN-483H 33 
CIN-371H 33 ^ - 4 4 I L 16 CIN-485H 16 
CIN-376H 31 CIN-444H 16 C m - 4 8 7 ^ _ _ 3 3 _ _ 
CIN-377L - CIN-445H 18 CIN-490H 52 
CIN-378H 16 CIN-449L - 18 
CIN-379H 31 CIN-450H — 16 0 ^ - 4 9 5 1 ^ 
CIN-383H 58 CIN-451H 16 
CIN-387H 52 CIN-452L 16 
CIN-391L - CIN-454L 58 一 CIN-499l7~ - — 
CIN-395H 33 CIN-455H 18 CIN-500H 16 
CIN-396H - CIN-456H 16 — C I N - 5 Q 1 H ^ _ ^ 1 _ _ 
CIN-397L - CIN-457H 16 CIN-502l7~ 33 一 
CIN-398H 16 CIN-458H 18 CIN-505H 52 
CIN-398L 16 CIN-459H 18 CIN-507H 33 
CrN-399H 16 CIN-460L 58 CIN-SOSlT" 58 _ 
CIN-400L 52 CIN-461H 16 CIN-509ir~ 16 _ 
CrN-4Q5H 31 CIN-462H 16 CIN-SlQlT" 16 — 
CIN-405L 31 CIN-463H 16 CIN-511H 
CIN-406H 16 ^ - 4 6 4 H 52 CIN-512H 16 一 
CIN-408L - CIN-469H 16 CIN-513H 16 
CrN-414H 31 CIN-47QH 33 CIN-514L~ 58 
CIN-417L 16 CIN-473L - CIN-517H 33 
CIN-418H 52 CIN-474H 33 CIN-518L -
CIN-419H 16 CIN-477H 52 
CIN-420H 52 CIN-478H 16 CIN-SZSlT" 52 
CIN-428L 58 CIN-48QH 5 8 ~ C I N - 5 2 g ^ _ _ J 8 _ _ 
^ - 4 3 5H 16 |ciN-481H | 31 | - | _ 
(-)HPV-negative 
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Table 4.4.1b HPV Typing in Cervical Carcinoma (n = 93) 
Patient Code HPV type IPatient C ^ HPV type Patient Code I HPV type 
C-254 16 C-366 - C-445 58 
C-270 18 c"-367 16 C^48 16 
C-271 16 C-370 - C-449 16 
C-275 16 C-371 16 C-451 52 
C-277 58 C-372 33 C-455 16 
C-278 — 18 ^ 7 6 52 C-461 16 
C-279 — 16 ^ 7 7 16 C-474 -
C-280 — 16 c"-384 16 ^ 8 1 16 
C-290 16 ^-386 16 ^ 8 2 16 
C-300 ~ 16 ^ 9 4 16 C-483 33 
C-302 — 16 ^-395 — 16 C^87 -
C-307 — 16 M 9 9 16 C-488 
C-310 — 33 ^-401 58 ^ 8 9 16 — 
C-3 22 C j 0 3 _ _ _ _ C-492 1 
C-326 16 C-404 52 C-495 33 
C-328 — 11 c"-405 — - ^ 0 0 52 
C-334 — 16 ^-407 - C^02 70 
C-3 3 5 16 
C-337 — 16 C-409 16 C-511 5 2 = 
C-339 - C-410 - 一C-512 — 16 — 
C-340 — 18 ^ 1 9 58 C-513 -
C-343 ~~ 16 ^ 2 0 - C-517 
C-345 — 18 C-421 16 C-518 
C-346 16 C-422 - C-524 
C-349 58 C-425 33 C-525 
C-350 16 C-427 16 — C - 5 2 7 18 
C-353 16 C-428 - C-530 
C-356 0^433 i T ^ C-532 1 
C-358 16 C-435 16 ~ C - 5 3 5 16 
C-359 52 C:438 16 — C-538 16 
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Table 4.4.1c HPV Typing in CIN-L, CIN-H and Cervical Carcinoma 
Number of Type-specific HPV-positive (%) 
CIN-L CIN-H Cervical Carcinoma 
(n = 24) (n = 59) (n = 93) 
HPV-positive 15 (62.5) 57 (96.6) 79 (84.9) * 
HPV-11 0 (0.0) 0 (0.0) 1(1.1) 
HPV-16 4(16.7) 24(40.7) 5 2 ( 5 5 . 9 ) * * 
HPV-18 1 (4.2) 4(6.8) 6(6.5) 
HPV-31 1(4.2) 6(10.2) 1(1.1) 
HPV-33 2 (8.3) 8 (13.6) 5 (5.4) 
HPV-52 1(4.2) 10(16.9) 6(6.5) 
HPV-58 6 (25.0) 5 (8.5) 6 (6.5) 
HPV-67 0 (0.0) 0 (0.0) 1 (1.1) 
HPV-70 0 (0.0) 0(0.0) 1 (1.1) 
* 
The incidence of HPV infection in CIN-L, CIN-H and Cervical Carcinoma was 
62.50/0，96.6% and 84.9% respectively. The difference was statistically 
significant (p = 0.0003). In addition, the incidence of HPV infection in CIN-H 
was higher than that in CIN-L (p = 0.0001). 
* "k 
The incidence of HPV-16 infection in CIN-L, CIN-H and Cervical 
Carcinoma was 16.7%, 40.7% and 55.9% respectively. The difference was 
statistically significant (p = 0.0016). 
V 
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4.4.2 Correlation of MSI-positive with HPV Infection in 
Cervical Carcinoma 
Among 79 (84.9%) cases of HPV infection in cervical carcinoma, 23 (29.1%) 
cases showed MSI in at least one locus, 8 (10.1%) cases showed MSI in at least 
two loci and 7 (8.9%) cases showed MSI in at least three loci (Table 4.4.2). 
There was no significant correlation between the presence of MSI and HPV 
infection in cervical carcinoma (p > 0.05). 
Within 23 (29.1%) cases of MSI-positive in at least one locus, seven types of 
HPV were detected. These included HPV-16 in 16 of 52 (30.8%) cases, HPV-18 
in 1 of 6 (16.7%) case, HPV-31 in 1 of 1 (100.0%) case, HPV-33 in 1 of 5 (20.0%) 
case, HPV-52 in 2 of 6 (33.3%), HPV-58 in 1 of 6 (16.7%) case and HPV-67 in 1 
of 1 (100.0%) case (Table 4.4.2). There was also no significant correlation 
between the presence of MSI in at least one locus and any type-specific HPV 
infection in cervical carcinoma (p > 0.05). 
V 
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Table 4.4.2 Correlation of MSI-positive with HPV Infection in Cervical 
Carcinoma (n = 93) 
All Number of MSI-positive (%) 
Patients At least 1 locus At least 2 loci At least 3 loci 
HPV-positive 79 23 (29.1) 8 (10.1) 7(8.9) 
HPV-11 1 0(0.0) 0(0.0) 0(0.0) 
HPV-16 52 16 (30.8) 7 (13.5) 6 (11.5) 
HPV-18 6 1(16.7) 0(0.0) 0(0.0) 
HPV-31 1 1(100.0) 0(0.0) 0(0.0) 
HPV-33 5 1 (20.0) 0(0.0) 0(0.0) 
HPV-52 6 2 (33.3) 1 (16.7) 1 (16.7) 
HPV-58 6 1 (16.7) 0 (0.0) 0 (0.0) 
HPV-67 1 1 (100.0) 0 (0.0) 0(0.0) 
HPV-70 1 0 (0.0) 0 (0.0) 0 (0.0) 
HPV-negative 14 4(28.6) 4 (28.6) 4(28.6) 
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5.1 MSI Detection 
In 1993，one of the classes of microsatellites with dinucleotide repeats was 
found to be unstable in some human cancers (Aaltonnen et al., 1993; lonov et al., 
1993 & Thibodeau et al., 1993) and in cancer occurred in patients with one of the 
cancer-prone syndromes, hereditary non-polyposis colorectal cancer (HNPCC) 
(Aaltonnen et al., 1993 & Peltomaki et al., 1993). As mutations in genes 
functioning in DNA mismatch repair are inherited in pedigrees of HNPCC (Fishel 
“al., 1993 & Leach et al., 1993), this phenotype, 'microsatellite instability', was 
regarded as an important phenotype in cells deficient in DNA mismatch repair 
and, consequently, as a marker of a high risk for cancer. MSI analysis is, indeed, 
an efficient approach for detecting defective DNA mismatch repair, since 
mismatch repair genes have no marked hot-spots for mutations (Liu et al., 1996; 
Nystrom-Lahti et al., 1996; Beck et al., 1997 & Weber et al., 1997) and 
sometimes undergo epigenetic silencing due to an altered methylation in their 
promoter regions (Ahuja et al., 1997; Kane et al, 1997; Cunningham et al., 1998; 
Herman et al., 1998 & Veigl et a/., 1998). 
Since MSI has been observed in many cases of sporadic cancers 
(Gonzalez-Zulueta et al” 1993; Lothe et al., 1993 & Risinger et al., 1993), 
numerous studies on MSI has been done in a wide variety of human malignancies, 
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from biological, medical and social points of view. However, the differences of 
MSI results were widely reported in the literature (Han et al., 1993; Ruschoff e/ 
a/.，1995; Arzimanoglou et al, 1998 & Claij and Riele, 1999). Besides the 
different tumors from different populations were examined, the discrepancies 
may also be related to the methodology used. As various methods to detect MSI 
have been devised, appearances of data in the literature are diverse. In addition, 
different sets of microsatellite markers have been used; hence a comparison of 
results from independent groups is difficult. These circumstances had raised a 
serious confusion in this field. 
In 1997, the National Cancer Institute (NCI) sponsored The International 
Workshop on Microsatellite Instability and RER Phenotypes in Cancer Detection 
and Familial Predisposition' in order to review and unify this field (Boland et al., 
1998). In this workshop, several important conclusions were reached. 
Concluding that 'a variety of techniques to characterize microsatellite instability 
has been found to be equally effective' (Bocker et al, 1997), they attributed the 
diversity in data mainly to the variety of microsatellites used, therefore, a panel of 
five microsatellites was recommended as 'working reference panel'. However, it 
would appear unlikely that the diversity in data derives merely from variety of 
microsatellites used. Besides, the definitions and criteria used to define the MSI 
phenotype of particular tumors were established. Considering the potential of 
microsatellite analyses to be used as a clinical test, inaccuracy of low 
reproducibility appears to be critical. 
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5.1.1 Techniques in MSI Assays 
Methods to detect alterations in repeat sequences can be divided into two 
categories, ones to directly observe changes on the genome using PCR and the 
others to observe reversion or inactivation of marker gene sequences including 
artificial repeat sequences (Henderson and Petes, 1992; Parsons et al., 1993; 
Strand et al., 1993; Heale and Petes, 1995 & Hanford et al., 1998). However, 
one of the ultimate goals in microsatellite analyses is to assess the risk for cancer 
in a given patient, using clinically obtained specimens. PCR has dominated this 
field since microsatellite sequences were first defined using PCR (Litt and Luty, 
1989 & Weber and May, 1989). 
Besides the reproducibility of PCR, an accurate electrophoresis is essential 
in microsatellite assays, so sequencing gel electrophoresis has been used (Weber 
and May, 1989). However, affected by various factors including temperature on 
a gel, migration of DNA fragments in a sequencing gel is not error-free, although 
some investigators reported highly precise electrophoresis in a classical 
sequencing gel (lonov et al., 1993; Shibata et al., 1994 & Casares et al., 1995). 
There were three techniques widely applied to the detection of microsatellite 
changes: (a) silver and ethidium bromide staining of polyacrylaminde gels; (b) 
radioactive labeling; and (c) automated fluorescence detection. The 
� 
identification of highly unstable tumors and tumors without MSI was achieved in 
high concordance (Bocker et al” 1997). 
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The techniques for a PCR-based microsatellite analysis are generally simple 
and do not require more than routine laboratory equipment plus a thermal cycler 
and a sequencing gel electrophoresis unit. In the detection of MSI in colorectal 
cancers，Schlegel et al. reported that silver staining were sensitive and highly 
reproducible (Schlegel et al., 1995), which also supported the results ofBudowle 
et al.'s study (Budowle et al., 1991) and lonov et al.'s study (lonov et al., 1993). 
Therefore, the method with silver and ethidium bromide staining of 
polyacrylaminde gels are widely applicable. 
In many of the conventional MSI assays, PCR products are labeled using a 
-radiolabeled nucleotides or y - radiolabeled primers, then autoradiography of 
the gel is done. In fact, working with radiolabeled material is not necessarily 
required (Bocker et al., 1997). Moreover, X-ray films used in autoradiography 
have highly biased detection characteristics, which can lead to a loss of fragments 
with a low signal or to a wrong estimate of the signal magnitude in fragments 
with a high signal. When Southern blotting is used for detection (Bhattacharyya 
et al, 1994 & Zhou et al., 1997)，the detection characteristic may become more 
biased，since Southern blotting itself has unique characteristics in trapping probe 
molecules onto a nitrocellulose membrane. 
Technologies to label nucleic acids with fluorescent dye compounds have 
evolved and a combination of fluorescent labeling and laser scanning led to a new 
technique for nucleic acid electrophoresis (Maehara et al., 2001). Automated 
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sequencing is one important outcome. Since some automated DNA sequencers 
are equipped with a program for fragment analyses, various types of genomic 
analyses are now made using fluorescent systems (Figeys et al., 1994; Hahn et al., 
1995; Lindqvist et al., 1996; Yip et al., 1996; Niederacher et al., 1997 & Paulson 
et al., 1999). In some systems, migration of each DNA fragment is completely 
standardized, since marker molecules with a different fluorescent dye can be 
co-electrophoresed. Therefore, the correct size of a given DNA fragment is 
known with an accuracy of less than one base. Then MSI can be determined 
precisely and clearly (Dietmaier et la., 1999). Indeed, use of an automated 
sequencer for microsatellite analyses is on the increase. 
In our study, y - radiolabelled primer with PCR-based method was used to 
detect the presence of MSI. Clear shifting or gaining of electrophoretic bands 
were recorded by comparing paired tumor with blood DNA, which were scored 
as MSI-positive. Results showed that the incident rates of MSI in cervical 
carcinoma were 29.0% in at least one of the ten loci, 17.2% in two or less loci 
(MSI-L) and 11.8% in three or more loci (MSI-H). Our results of MSI 
incidence in cervical carcinoma are higher than some pervious reports, such as 
Larson et al., 1996; Chu et al., 1998; Rodriguez et al., 1998 & Ou et al., 1999， 
suggesting that radioactive labeling is sensitive and highly reproducible. In 
order to confirm the incidence of MSI in cervical carcinoma, laser scanning of 
fluorescent-labeled fragments for microsatellite analysis is recommended for 
further study, which gives quantitative results and may be more feasible for 
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microsatellite analysis (Oda et al., 1997). However, the initial cost of 
equipment is too expensive. 
5.1.2 Choice of Microsatellite Markers 
MSI can be detected by examining microsatellite repeat fragments, as the 
numbers of repeats in some of the microsatellites can change due to the defective 
DNA repair (Aaltonen et al., 1993; lonov et al., 1993 & Thibodeau et al., 1993). 
MSI also occurs in a subset of sporadic colorectal carcinomas (lonov et al., 1993. 
Thibodeau et al., 1993 & Thibodeau et al., 1998). However, the efficient 
identification of tumors with MSI is important because it provides a valuable 
criterion for identifying patients whose DNA should undergo the work-intensive 
process of mutation screening for mismatch repair genes. Thus, microsatellite 
markers used for MSI assays in particular tumors should be selected with caution. 
A panel of five microsatellite markers (BAT 25, BAT 26, D2S123, D5S346 
and D17S250) was identified at a recent NCI Workshop as being efficient 
markers for detection of MSI (Boland et al., 1998). These markers are detected 
using PCR. Although MSI is known to occur in both colorectal carcinomas and 
extracolonic malignancies, the recommendations for the use of these markers 
pertain only to colorectal carcinoma (Frazier et al., 2000). These markers were 
encouraged to be evaluated for detection of MSI in other tumors. 
In our study of MSI in cervical carcinoma, the panel of five microsatellite 
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markers (BAT 25, BAT 26, D2S123, D5S346 and D17S250) recommended by the 
NCI Workshop was examined. The incidence of MSI in at least one locus was 
19 of 93 (20.4%). These included 10 of 93 (10.8%) cases of MSI-L (i.e., one 
marker is unstable) and 9 of 93 (9.7%) cases ofMSI-H (i.e., two or more of five 
markers are unstable). Besides, MSI were observed in 9 (9.7%) cases at BAT 25, 
1 (1.1%) case at BAT 26, 8 (8.6%) cases at D2S123, 9 (9.7%) cases at D5S346 
and 11 (11.8%) cases at D17S250. 
Recently, it has been shown that the microsatellite marker BAT 26 is a 
sensitive marker of MSI, even if studied as the one and only locus (Dietmaier et 
a/.，1997 & Hoang et al, 1997). Study of BAT 26 was confirmed that it was 
unstable in all the "high" MSI tumors (Bocker et al., 1997). However, MSI-H 
cervical carcinomas were described that did not display instability at the BAT 26 
locus in our study. There was only 1 (1.1%) case shown MSI at this locus. 
Similar result was found in Ou et al. that only 1 (1.3%) of 80 cases shown MSI in 
cervical carcinoma (Ou et al., 1999). Since BAT 26 is a poly(A) tract in an 
intron ofhMSH2, it was supposed that BAT 26 may be implicated in cancers that 
are closely related to MMR genes, such as HNPCC or colorectal cancer, and 
should not be a routine method for detecting the status of RER in all cancers with 
MSI (Ou et al., 1999). 
MSI at multiple loci has been shown to result from defects in the mismatch 
repair genes in colorectal carcinomas and other tumors related to the HNPCC 
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syndrome (Aaltonen et al., 1993; Fishel et al., 1993 & Leach et al., 1993). 
However, the cause of MSI at isolated loci is still unknown. Susceptibility to 
MSI is thought to be highly dependent on the number of repeats and the length of 
repeat units, since the former determines the susceptibility of DNA polymerases 
to slippage (Greene and Jinks-Robertson, 1997 & Tran et al., 1997) and the latter 
determines workability of the mismatch recognition complexes on repeat units 
looping out of the strand (Sia et al., 1997). There is a suggestion that some 
background instability of microsatellite exists that depends on the repeat type 
(Mahtani and Willard, 1993 & Weber and Wong, 1993). A combination of 
mono-, di-, and trinucleotide repeats and complex dinucleotide repeats is able to 
detect all MSI tumors reliably (Dietmaier et al., 1997). Thus, the microsatellite 
panel should comprise different repeat types from different chromosomes. 
Several mononucleotide repeats, such as the ones defined by BAT 25, BAT 
26 and BAT 40 (Dietmaier et al,, 1997; Hoang et al., 1997 & Zhou et al., 1997)， 
have proven to be very useful for the identification of the MSI-H group of tumors. 
The separation of shortened unstable alleles can be clearly distinguished from the 
normal allele in the majority of cases. Although mononucleotide repeats were 
reported to be useful to detect MSI (Dietmaier et al., 1997; Hoang et al., 1997 & 
Percesepe et al., 1998)，correlation between mononucleotide MSI and mutation in 
major mismatch repair genes were not seen (Percesepe et al., 1998). 
Larson et al. (Larson et al., 1996) reported that dinucleotide repeat loci were 
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much more prone to instability compared with tri- and tetranucleotide repeats, 
and they observed that this fact was unique to cervical cancer. However, 
alterations in colorectal cancers were seen at mono-, di-，tri- and tetranucleotide 
repeat sequences in the RER-positive tumors. In contrast, breast cancers display 
instability preferentially at tri- and tetrarepeats (Wooster et al., 1994), though a 
similar has not been found in cervical cancers (Larson et al., 1996). In the study 
of Helland et al., possible alterations at 8 dinucleotide loci were examined 
mapping to 6 different chromosomes in endometrial and cervical cancers 
(Helland et al., 1997). Their findings suggested that MSI at one or a few loci 
may represent a random event but could not rule out the possibility that a 
component of the MMR system, which does not cause a severe mutator 
phenotype at dinucleotide loci, might be the underlying cause. 
In our study, the 2nd panel of five microsatellite markers (BAT 40，D3S1263, 
D4S402，D5S406 and D11S912) from chromosome 1，3，4，5 and 11 was 
examined. The incident rates of MSI in at least one locus, MSI-L and MSI-H 
were the same as that in the 1st panel markers. Furthermore, the correlation of 
MSI-positive from both panels with clinicopathological characteristics in cervical 
carcinoma was similar, but significant correlation was found statistically between 
the presence of MSI in the 2nd panel and the clinical status, i.e. patients with MSI 
positive invasive cervical carcinomas had significantly poor prognosis. Same 
correlation was also observed in the incidence of MSI from total ten 
microsatellite markers. From this point of view, although the 2nd panel of five 
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microsatellite markers demonstrates the same incident rate of MSI as the 1st 
panel does, it presents a statistically significant correlation between the presence 
of MSI and clinical status, which is essential for a prognostic marker. Since 
valuable results are also observed in the analysis of only five microsatellite 
markers，in order to decrease the consuming of limited tumor DNA, reagents and 
times for experiments, these microsatellite markers are recommended for MSI 
detection in cervical neoplasm. 
5.1.3 Diagnostic Criteria of MSI 
Various diagnostic criteria for MSI have been used, which made it difficult 
to compare the positivities reported from independent groups and have 
contributed to the confusion in this field. In the NCI workshop on MSI in 
December 1997，phenotypes with MSI were classified into two categories: 
MSI-high frequency (MSI-H) and MSI-low frequency (MSI-L) (Boland et al., 
1998). The first is defined as ones showing microsatellite alterations in 'the 
majority of markers' and the second exhibiting changes only in 'a minority of 
markers'. These two categories may correspond to Thibodeau et al.'s Type I and 
Type II mutations (Thibodeau et al., 1993)，since in the report Thibodeau et al. 
described that all tumors with Type I mutations showed changes in multiple loci 
and that Type II mutation was observed mainly at a single locus. 
• At the NCI Workshop, tumors were defined as possessing MSI-H if two or 
more of five markers are unstable. If greater than five markers are used to 
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identify these particular tumor phenotypes，then it was recommended that the 
criteria be modified to reflect the percentage of markers demonstrating instability. 
Therefore, MSI-H would be defined as having MSI in more than 30% to 40% of 
the markers tested，and MSI-L would exhibit MSI in less than 30% to 40% of the 
markers. If none of the markers display MSI, then the tumor would be 
microsatellite stable (MSS). 
According to the diagnostic criteria for MSI in NCI Workshop, only 1 of 59 
(1.7%) cases of CIN-H was categorized as MSI-L in our study. In the 
investigation of cervical carcinoma, 16 of 93 (17.2%) cases were categorized as 
MSI-L and 11 of 93 (11.8%) cases were categorized as MSI-H. 
As the MSI assay is applied to clinical testing in the future, further analysis 
of those tumors demonstrating instability in only one or two shifted loci should 
be considered. This may allow the determination of the validity of studying a 
limited (e.g. five or fewer) number of markers. Furthermore, such studies may 
provide more detailed information to determine whether the MSI-L and MSS 
groups should or should not be separated. Additional data may also help in the 
identification of the genes responsible for the presence of low-level instability in 
the MSI-L group. Besides, such information will be critical for future 
comparison of new loci and clinical correlation, as well as providing the potential 
for merging data sets. It may also help eliminate redundant markers and replace 
them with more information ones. 
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5.2 The Role of MSI in the Carcinogenesis of Cervical Neoplasm 
Cervical Carcinoma is one of the most common malignancies affecting 
women worldwide and primarily arises for continuously progressive 
premalignant lesions defined as mild to severe dysplasia (Anderson et al., 1991). 
Since the prognosis for invasive cervical carcinoma is generally poor, whereas 
most of the precursor lesions are often readily curable, the dissection of the 
molecular events that mediate the pathological changes from noninvasive to 
invasive tumors is of considerable important. 
In recent years, defects in DNA repair pathways as a route for human 
carcinogenesis has been recognized and the use of the MSI assay to recognize 
tumors with such defects has been established. The mechanism responsible for 
MSI has not been elucidated but may include abnormalities in recombination 
(intra- and inter-chromosomal) and errors in DNA repair or synthesis so that MSI 
has been referred to as a replication error (RER) phenotype. Since MSI has 
been documented in a premalignant stage of tumorigenesis in HNPCC (Aaltonen 
al., 1994) and in colitis-associated colorectal dysplasias (Suzuki et al., 1994), 
these genetic alterations are observed to be an early event in tumorigenesis that 
persists after transformation (Shibata et al., 1994). Thus, MSI should be found 
in benign as well as malignant tumors. 
� 
. In the study of genetic alterations in the progression of precancerous lesions 
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of the uterine cervix, replication error-type alterations were noted in the 5pl4-ter 
region in six (13%) of 46 invasive carcinomas, two (40%) of five cases of CIS, 
and three (21%) of 14 precancerous lesions. MSI at the locus D5S406 was 
shown in four (8.7%) of 46 invasive carcinomas (Mitra et al., 1995). This study 
revealed frequent replication errors in precancerous lesions as well as in 
carcinomas, suggesting that the genetic instability in 5p is an early change in 
cervical carcinogenesis. 
To further understand the role of MSI in cervical carcinogenesis, we 
evaluated the status of MSI in CIN and invasive cervical carcinoma at ten loci 
BAT 25, BAT 26, D2S123, D5S346, D17S250, BAT 40, D3S1263, D4S402, 
D5S406 and D11S912. To investigate whether MSI was an early event in 
cervical tumorigenesis, and whether it led to the spread of the dysplasia to higher 
levels of the cervical epithelium. Results showed that MSI were observed (in at 
least one locus) in 0 of 24 (0.0%) case in CIN-L, 1 of 59 (1.7%) case in CIN-H 
and 27 of 93 (29.0%) cases in cervical carcinoma. The more severe the cervical 
neoplasm developed, the higher the incident rate of MSI was detected. The 
difference was statistically significant (p = 0.0000). Moreover, the incident rate 
of MSI in cervical carcinoma was statistically higher than that in CIN-H (p = 
0.0006). 
Our data indicate thafMSI is rare in CIN, and suggest that it may be not 
necessarily involved in malignant transformation. This result was also 
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confirmed in the Jimenez et al.'s study. Although we cannot rule out the 
presence of other genotypes that were not tested in this study of CIN, it is also 
probable that additional factors are involved in the initiation of genetic instability 
(Jimenez et al., 1998). 
A major explanation for the difference in the incidence of MSI is the 
selection of microsatellite samples. Most studies of MSI in SILs examined SILs 
adjacent to invasive cancers. In the Chu et al.'s study, a high frequency of MSI 
was found in CIN-L (41%) and CIN-H (67%), but not in cervical carcinoma 
(5.3%). However, MSI was more frequently found in CIN-L in association with 
invasive cancers than in those associated with CINs (Chu et al., 1999). On the 
contrary, in the current study, we examined CIN without concomitant invasive 
cancer. 
In the current study, MSI were detected (in at least one locus) in 27 of 93 
(29.0%) cases in cervical carcinoma, which was statistically higher than the 
incidence of MSI in CIN-H (p = 0.0006). We suggest that MSI may be a late 
event in cervical tumorigenesis. Recently, a study reported that MSI was 
detected in 8 (22.9%) of 35 invasive cancers and in 1 (2.7%) of 37 early stage 
cancers (microinvasive cancer and carcinoma in situ). These results also 
suggested that MSI was a late event and occurred after CIS developed to an 
invasive phenotype (Nishimura et a/., 2000). 
Our observation of 27 (29.0%) cases with MSI in at least one locus in 97 
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cervical carcinomas is similar to the result (25%) of a recent study (Chung et al., 
2001). However, the result is higher than some previous reports. Han et al. 
reported MSI in two out of 13 (15%) cases of cervical cancer, detected as shift 
bands in at least one of four microsatellite markers on chromosomes 2, 3 and 17 
(Han et al., 1993). Larson et al. using a total of 30 microsatellite di-, tri-, and 
tetranucelotide markers on chromosomes 3p, 4 and l lq (Larson et al., 1996) 
found MSI at two or more loci in 6% of 89 cervical carcinomas and Helland et al. 
found a prevalence of 6% (Helland et al., 1997). Defects in DNA 
repair-associated genes rarely acquired and do not supersede allelic loss during 
cervical carcinogenesis (Larson et al., 1996). The differences may result from 
the different of methods used to detect MSI. 
In three previous studies, the potential role of MMR gene defects in cervical 
cancer has been investigated by using the conventional radioactively based 
method for detection of microsatellite alterations. The frequency of MSI (novel 
alleles at one or more loci) found in the respective series have ranged from 6% to 
350/0 (Han et al., 1993; Helland et al., 1997 & Wistuba et al., 1997). These 
differences in results among the above reports could be explained by the 
variations in the type and number of loci examined, the number of patients 
analyzed, and the characteristics of the method used for MSI assessment, which 
relies on the visual evaluation of radiographs. Similarly, a range of rates of MSI 
V 
(55% to 91%) has also been in familial colon cancer. 
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Generally, cervical carcinomas rarely showed MSI. There have been many 
reports of allelic losses in cervical carcinoma (Kohno et al., 1993; Mitra et al., 
1995; Mullokandov et al., 1996; Ku et al., 1997 & Chu et al., 1998). This was 
also confirmed in the study of Rodriguez et al. and Ou et al., which MSI was 
observed only in 3 (5.6%) of 54 cases and 3 (3.8%) of 80 cases in cervical 
carcinoma respectively (Rodriguez et al., 1998 & Ou et al., 1999). According to 
the study by Farrington et al. (Farrington et al., 1998), the sensitivity of MSI 
status to analyze mutation of hMSH2 and HMLHl was 86 % and specificity was 
73% in their colon cancer patients. From these results, although a low incident 
rate of MSI in cervical cancer was found in many studies, this was unable to rule 
out a few cases, which had no MSI but did have MMR mutation. 
5.3 The Clinical Significant of MSI in Cervical Carcinoma 
The relationship between MSI and clinical characteristics may vary with 
tumor type. For example, MSI in urinary bladder cancer occurs in low stage 
tumors (Gonzaler-Zulueta et al., 1993) and in colorectal cancer is associated with 
a good prognosis (Thibodeau et al., 1993). Tangir et al. reported that borderline 
ovarian tumors exhibit a significantly higher frequency of MSI when compared 
with invasive epithelial ovarian tumors (Tangir et al., 1996). In addition, dos 
Santos et al. reported that patients with gastric tumors with multiple MSI positive 
loci have a better clinical outcome (dos Santos et al., 1996). Lukish et al. 
reported that patients with MSI positive colonic tumors have significantly better 
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prognosis (Lukish et al., 1998). However, in breast carcinoma patients a 
statistically significant correlation between the presence of MSI and poor 
prognosis has been reported (Paulson et al., 1996). These discrepancies suggest 
the need to expand the studies to a large number of tumors of multiple tumor type 
to determine whether MSI can be used as prognostic indicator. 
In the cervix, no significant correlation was observed between the presence 
of MSI and clinicopathological characteristics (Nishimura et al., 2000). In the 
study of Larson et al. and Helland et al., results also did not show a relationship 
with tumor type, stage, grade, or HPV status (Larson et al., 1996 & Helland et al., 
1997). Besides, there was no significant correlation between the allelotypic 
changes and clinical profiles such as age, tumor differentiation, and lesion size 
(Chu et al, 1999). 
However, the current study showed a trend of MSI positivity toward higher 
grade and advanced stage. In the clinical status, within 67 patients who were 
alive with or without disease, MSI-positive in at least one locus was observed in 
15 (22.4%) cases, but it was observed in 12 of 26 (46.2%) patients who had died 
of disease. The difference was statistically significant (p = 0.0443). Thus, we 
suggest that patients with MSI positive invasive cervical carcinomas may have a 
poor clinical outcome, i.e. a significantly poor prognosis may be found. 
• The contrasts between the different prognoses associated with MSI in colon 
and cervical cancer suggest that there is either a gap in our understanding of how 
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defective MMR ultimately affects genomic stability, or that the actions of a 
specific mutational mechanism may have variable outcomes in cells of different 
tissues (Paulson et aL, 1996). In the proximal colon, MSI-positive tumors are 
limited in their invasiveness on the basal side by the muscularis, grow into the 
lumen, where the potential routs of metastasis are more limited. An alternative 
that is not exclusive of the above possibility is that the different underlying 
mutations in colorectal and cervical cancer may act either to moderate or 
intensify the effects of MSI on tumor progression. Thus, the same mutational 
mechanism could have different effects depending on the genetic background of a 
particular neoplasm. 
Valuable molecular markers may one day help us decide which patients with 
invasive cancers are likely to develop recurrences or second primaries. The 
correlation between the presence of MSI and poor prognosis in cervical cancer 
patients brings out the need for further examination of this phenomenon in this 
and other types of human cancers. Since recurrent disease of cervical cancer is 
seldom curable, careful choice of a primary therapy for cervical carcinoma is 
critical. In addition to the potential prognostic value, identification of 
MSI-positive tumors may allow more effective therapies to be pursued. 
5.4 The Interaction between HPV Infection and MSI in Cervical 
� 
Carcinoma 
While the occurrence of CIN is a common and early manifestation of 
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cervical infection by oncogenic HPV, especially type 16 (Koutsky et al, 1992), 
cervical cancer occurs years after the appearance of CINs (Wright et al., 1994a & 
Wright et al., 1994b). Intra-epithelial lesions can be found associated with 
cervical cancer, and are probably the precursors of adjacent invasive lesions. 
However, the large majority of CINs - even high-grade lesions - spontaneously 
regress, which indicates that additional events to those observed in the most 
commonly encountered CINs, which do not evolve into cancer, are required for 
conversion to malignancy (Green and Donovan, 1970). 
Although infection of cervical epithelial cells with certain "aggressive" HPV 
subtypes substantially increases the relative risk for cervical dysplasia (Ponten et 
a/.，1995), several lines of evidence suggest that HPV infection alone does not 
lead to overt malignancy (zur Hausen, 1989 & Howley, 1991). Somatic cell 
(Stanbridge et al., 1981)，cytogenetic (Atkin et al., 1990), and molecular genetic 
studies (Mitra et al., 1994) strongly support the notion of a multistep genetic 
model for cervical tumorigenesis. 
In our study, the incidence of HPV infection in CIN-L, CIN-H and cervical 
carcinoma was 62.5%, 96.6% and 84.9% respectively. The difference was 
statistically significant (p = 0.0003). In addition, the incidence of HPV infection 
in CIN-H was higher than that in CIN-L (p = 0.0001). Moreover, the incidence 
of HPV-16 infection in CIN-L (16.7%), CIN-H (40.7%) and cervical carcinoma 
(55.9%) was statistically significant difference (p = 0.0016). Thus, the higher 
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incident rate of HPV-16 infection was observed in the more severe type of 
cervical neoplasm. 
However, among 79 cases of HPV infection in cervical carcinoma, 23 
(29.1%) cases showed MSI in at least one locus. There was no significant 
correlation between the presence of MSI and HPV infection or any type-specific 
HPV infection in cervical carcinoma (p > 0.05). Results from several studies 
confirmed that there was no significant correlation between the status of HPV 
infection and the status of MSI in CIN (Jimenez et al., 1998) or cervical 




Chapter VI Conclusion 
CHAPTER VI CONCLUSION 
MSI is typically found in tumors from with HNPCC patients (Aaltonen et al., 
1993) and has been reported in a wide variety of human malignancies, including 
sporadic colon and gastric cancers (Han et al, 1993; lonov et al., 1993 & 
Thibodeau et al., 1993). Although the precise mechanism by which these 
mutations lead to the development of cancer is unknown, cells with defective 
MMR function show a mutator phenotype, characterized by an increased 
mutation rate (Parsons et al,, 1993a). This in turn may lead to alterations in 
genes, which play a direct role in malignant cell transformation. 
Recently, many studies has reported the varies incidence of MSI in cervical 
cancer (Han et al, 1993; Mitra et al, 1995; Larson et al., 1996; Helland et al., 
1997; Wistuba et al., 1997; Chu et al, 1998; Fouret et al, 1998; Rodriguez et al, 
1998; Ou et al., 1999; Nishimura et al., 2000 & Chung et al., 2001) and its 
premalignant lesion (Mitra et al., 1995; Fouret et al； 1998; Jimenez et al., 1998; 
Chu et al., 1999 & Nishimura et al., 2000). The differences in results among the 
reports could be explained by the variations in the type and number of loci 
examined, the number of patients analyzed, the type of samples, the diagnostic 
criteria of MSI and the characteristics of the method used for MSI assessment. 
In the present study, MSI were observed (in at least one locus) in 0 of 24 
. (0.0%) case in ClN-L, 1 of 59 (1.7%) case in CIN-H and 27 of 93 (29.0%) cases 
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in cervical carcinoma. The more severe the cervical neoplasm developed, the 
higher the incident rate of MSI was detected statistically significant, suggesting 
that MSI may be a late event in cervical tumorigenesis. 
Moreover, the results showed that there is a trend of MSI positivity toward 
higher grade and advanced stage. In the clinical status, the incidence of 
MSI-positive for patients who were alive with or without disease are statistically 
lower than that who had died of disease. Thus, we suggest that patients with 
MSI positive invasive cervical carcinomas may have a poor clinical outcome, i.e. 
a significantly poor prognosis is found. Since recurrent disease of cervical 
cancer is seldom curable, careful choice of a primary therapy for cervical 
carcinoma is critical. MSI assay may become a potential prognostic indicator 
for deciding the therapies used for MSI-positive patients. On the other hand, no 
correlation is found between the status of MSI and the HPV infection. 
Besides, the five microsatellite markers that we chose for MSI detection, i.e.， 
BAT 40, D3S1263, D4S402, D5S406 and D11S912，demonstrates the same 
incident rate of MSI as the panel of microsatellite markers recommended by the 
NCI Workshop. Our results of MSI incidence in cervical carcinoma are even 
higher than some pervious reports, such as Larson et al., 1996; Chu et al., 1998; 
Rodriguez et al, 1998 & Ou et al., 1999. Moreover, results only from this panel 
of microsatellite markers�present a statistically significant correlation in 
MSI-positive patients with poor clinical outcome. As a result, these 
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microsatellite markers are recommended for MSI detection in cervical neoplasm. 
In conclusion, the correlation between the presence of MSI and poor 
prognosis in cervical cancer patients brings out the need for further examination 
of this phenomenon in this and other types of human cancers. In addition to the 
potential prognostic value, identification of MSI-positive tumors may allow more 
effective therapies to be pursued. Thus, a larger study using the above 
microsatellite markers with uniform methodology, based on the use of fluorescent 
DNA sequencing technology, is required to determine accurately whether MSI is 
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